cvm_10q.htm

0001654954-21-001609.txt : 20210212 0001654954-21-001609.hdr.sgml : 20210212 20210212161622 ACCESSION NUMBER: 0001654954-21-001609 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210212 DATE AS OF CHANGE: 20210212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 21627607 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 10-Q 1 cvm_10q.htm QUARTELRY REPORT cvm_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to ______________.

Commission File Number 001-11889

CEL-SCI CORPORATION

Colorado		84-0916344
State or other jurisdiction incorporation		(IRS) Employer Identification Number

8229 Boone Boulevard, Suite 802

Vienna, VA 22182

Address of principal executive offices

(703) 506-9460

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		CVM		NYSE American

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Class of Stock		No. Shares Outstanding		Date
Common		40,529,278		February 5, 2021

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Item 1.		Page

	Condensed Balance Sheets at December 31, 2020 and September 30, 2020 (unaudited)	3

	Condensed Statements of Operations for the three months ended December 31, 2020 and 2019 (unaudited)	4

	Condensed Statement of Stockholders’ Equity for the three months ended December 31, 2020 and 2019 (unaudited)	5

	Condensed Statements of Cash Flows for the three months ended December 31, 2020 and 2019 (unaudited)	6

	Notes to Condensed Financial Statements (unaudited)	8

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3.	Quantitative and Qualitative Disclosures about Market Risks	21

Item 4.	Controls and Procedures	21

PART II

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23

Item 6.	Exhibits	23

	Signatures	24

Table of Contents

CEL-SCI CORPORATION
CONDENSED BALANCE SHEETS

	DECEMBER 31,			SEPTEMBER 30,
ASSETS	2020			2020
	(UNAUDITED)
Current Assets:
Cash and cash equivalents	$	21,860,482		$	15,508,909
Receivables		54,922			54,922
Prepaid expenses		629,894			1,313,432
Supplies used for R&D and manufacturing		1,152,837			820,052

Total current assets		23,698,135			17,697,315

Finance lease right of use assets		13,382,401			13,811,849
Operating lease right of use assets		1,160,305			1,198,958
Property and equipment, net		9,401,891			5,843,993
Patent costs, net		300,356			313,422
Deposits		1,670,917			1,670,917

Total Assets	$	49,614,005		$	40,536,454


LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
Accounts payable	$	3,092,856		$	2,023,067
Accrued expenses		616,163			510,515
Due to employees		458,740			448,022
Derivative instruments, current portion		2,040,773			213,787
Lease liabilities, current portion		1,125,337			1,070,123

Total current liabilities		7,333,869			4,265,514

Derivative instruments, net of current portion		750,154			3,551,826
Finance lease obligations, net of current portion		11,495,840			11,753,100
Operating lease obligations, net of current portion		1,073,470			1,114,340
Other liabilities		125,000			125,000

Total liabilities		20,778,333			20,809,780

Commitments and Contingencies		-			-

STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding		-			-
Common stock, $.01 par value - 600,000,000 shares authorized; 39,767,058 and 38,730,150 shares issued and outstanding at December 31, 2020 and September 30, 2020, respectively		397,671			387,302
Additional paid-in capital		418,210,168			401,174,675
Accumulated deficit		(389,772,167	)		(381,835,303	)

Total stockholders' equity		28,835,672			19,726,674

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	49,614,005		$	40,536,454

See notes to condensed financial statements.

Table of Contents

CEL-SCI CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED DECEMBER 31, 2020 and 2019
(UNAUDITED)

	2020			2019

Grant income	$	-		$	35,506

Operating Expenses:
Research and development		5,414,760			4,252,813
General and administrative		3,316,156			2,638,896
Total operating expenses		8,730,916			6,891,709

Operating loss		(8,730,916	)		(6,856,203	)

Other income		-			18,448
Gain on derivative instruments		932,836			766,509
Other non-operating gains		121,606			790,669
Interest expense, net		(260,390	)		(250,783	)

Net loss		(7,936,864	)		(5,531,360	)
Modification of warrants		(85,779	)		-

Net loss available to common shareholders	$	(8,022,643	)	$	(5,531,360	)

Net loss per common share
BASIC	$	(0.21	)	$	(0.16	)
DILUTED	$	(0.21	)	$	(0.16	)

Weighted average common shares outstanding
BASIC		38,670,247			35,084,279
DILUTED		38,767,286			35,098,608

See notes to condensed financial statements.

Table of Contents

CEL-SCI CORPORATION
STATEMENTS OF STOCKHOLDERS' EQUITY
(UNAUDITED)

							Additional
	Common			Stock			Paid-In			Accumulated
	Shares			Amount			Capital			Deficit			Total

BALANCES AT OCTOBER 1, 2020		38,730,150		$	387,302		$	401,174,675		$	(381,835,303	)	$	19,726,674

Proceeds from the sale of common stock		1,000,000			10,000			13,549,500			-			13,559,500
Warrant exercises		15,000			150			89,100			-			89,250
Equity based compensation - employees		(2,000	)		(20	)		3,296,329			-			3,296,309
401(k) contributions paid in common stock		3,564			36			41,635			-			41,671
Stock and options issued to nonemployees for service		15,044			150			152,300			-			152,450
Option exercises		5,300			53			23,458			-			23,511
Modification of warrants		-			-			192			-			192
Share issuance costs		-			-			(117,021	)		-			(117,021	)
Net loss		-			-			-			(7,936,864	)		(7,936,864	)

BALANCES AT DECEMBER 31, 2020		39,767,058		$	397,671		$	418,210,168		$	(389,772,167	)	$	28,835,672

					Additional
	Common		Stock		Paid-In			Accumulated
	Shares		Amount		Capital			Deficit			Total

BALANCES AT OCTOBER 1, 2019		35,231,776	$	352,318	$	358,507,603		$	(353,726,254	)	$	5,133,667

Adoption of new accounting standard									2,146,195			2,146,195
Issuance of common stock		606,395		6,064		5,043,939			-			5,050,003
Warrant exercises		132,900		1,329		295,772			-			297,101
Equity based compensation - employees		-		-		1,800,225			-			1,800,225
401(k) contributions paid in common stock		4,474		45		40,892			-			40,937
Stock issued to nonemployees for service		15,819		158		84,289			-			84,447
Purchase of stock by officer		3,725		37		24,963			-			25,000
Share issuance costs		-		-		(92,150	)		-			(92,150	)
Net loss		-		-		-			(5,531,360	)		(5,531,360	)

BALANCES AT DECEMBER 31, 2019		35,995,089	$	359,951	$	365,705,533		$	(357,111,419	)	$	8,954,065

See notes to condensed financial statements.

Table of Contents

CEL-SCI CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
THREE MONTHS ENDED DECEMBER 31, 2020 and 2019
(UNAUDITED)

	2020			2019

Net loss	$	(7,936,864	)	$	(5,531,360	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		550,682			502,540
Share-based payments for services		248,660			155,740
Equity based compensation		3,296,309			1,800,225
Common stock contributed to 401(k) plan		41,671			40,937
Gain on derivative instruments		(932,836	)		(766,509	)
Modification of warrants		192			-
(Increase)/decrease in assets:
Receivables		532,328			(28,278	)
Prepaid expenses		(332,785	)		86,567
Supplies used for R&D and manufacturing		-			(123,512	)
Increase/(decrease) in liabilities:
Accounts payable		532,679			(393,064	)
Accrued expenses		143,028			80,432
Due to employees		10,718			76,520
Other liabilities		18,319			(1,914	)

Net cash used in operating activities		(3,827,899	)		(4,101,676	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(3,149,820	)		(101,820	)
Proceeds from the sale of equipment		-			4,500
Expenditures for patent costs		-			(12,390	)

Net cash used in investing activities		(3,149,820	)		(109,710	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		13,559,500			5,050,003
Payments of stock issuance costs		(79,499	)		(31,080	)
Proceeds from the purchase of stock by officer		-			25,000
Proceeds from exercises of warrants and options		70,911			297,101
Payments on obligations under finance lease		(221,620	)		(191,034	)

Net cash provided by financing activities		13,329,292			5,149,990

NET INCREASE IN CASH AND CASH EQUIVALENTS		6,351,573			938,604

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		15,508,909			8,444,774

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	21,860,482		$	9,383,378

See notes to condensed financial statements.

Table of Contents

CEL-SCI CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
THREE MONTHS ENDED DECEMBER 31, 2020 and 2019

	2020		2019
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment included in current liabilities	$	1,700,969	$	296,941
Capitalizable patent costs included in current liabilities	$	15,000	$	-
Finance lease obligation included in accounts payable	$	1,752	$	745
Prepaid consulting services paid with issuance of common stock	$	243,687	$	(71,293	)
Exercise of derivative liabilities	$	41,850	$	-
Financing costs included in current liabilities	$	88,021	$	76,650

Cash paid for interest	$	277,618	$	295,107

See notes to condensed financial statements.

Table of Contents

CEL-SCI CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED DECEMBER 31, 2020 AND 2019 (UNAUDITED)

A.	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2020.

In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary for a fair presentation of the Company’s financial position as of December 31, 2020 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2020 is derived from the September 30, 2020 audited financial statements.

The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.

Summary of Significant Accounting Policies:

Property and Equipment - Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Leases - The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment, over a period of time, in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. For purposes of calculating lease liabilities, lease and non-lease components are combined.

Table of Contents

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2020 and September 30, 2020.

Derivative Instruments - The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim reporting period.

Stock-Based Compensation - Compensation cost for stock-based awards to employees and non-employees is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation - Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.

The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s common stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Vesting of restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Table of Contents

Newly Adopted Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement - Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820).” Under the new standard, the amount and reason for a transfer between Level 1 and Level 2 of the fair value hierarchy is no longer required to be disclosed, but public companies are required to disclose a range and weighted average of significant unobservable inputs for Level 3 fair value measurements. The Company adopted the new standard on July 1, 2020 with no impact to the Company’s financial statements.

New Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted. All of the Company’s liability classified warrants will be expired by that date and the Company does not expect the adoption to have a significant impact on its financial statements. The effect, if any, will largely depend on the composition and terms of the financial instruments at the time of adoption.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements.

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

B.	OPERATIONS AND FINANCING

On May 4, 2020, the Company announced that the pivotal Phase 3 head and neck cancer study of Multikine immunotherapy had reached the targeted threshold of 298 events (deaths) required to conduct the data evaluation. Database lock has been completed and the Phase 3 study is now in the final statistical analysis phase. The Company will continue to remain blinded to the study results throughout this process. The Company will be advised of the results when the analysis is completed, and the study results will be announced to the public at that time.

The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similar to the way it has substantially funded operations for the past 12 months. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.

Table of Contents

To finance the Company through marketing approval, the Company plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because the Multikine Phase 3 study has ended and is only awaiting final data readout. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.

Impact of COVID-19 Pandemic

In response to the global outbreak of COVID-19 and the World Health Organization’s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention’s (“CDC”) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company’s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.

The financial statements have been prepared assuming the Company will continue as a going concern, but due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

C.	STOCKHOLDERS’ EQUITY

Proceeds from the Sale of Common Stock

In December 2020, the Company sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 30-day option to purchase up to an additional 150,000 shares of common stock at the public offering price to cover over-allotments.

Equity Compensation

Underlying share information for equity compensation plans as of December 31, 2020 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Options Plans		138,400		85,895		N/A		213
Non-Qualified Stock Option Plans		9,987,200		8,527,787		N/A		1,201,832
Stock Bonus Plans		783,760		N/A		348,660		435,067
Stock Compensation Plans		634,000		N/A		150,695		464,895
Incentive Stock Bonus Plan		640,000		N/A		614,500		25,500

Underlying share information for equity compensation plans as of September 30, 2020 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		138,400		85,895		N/A		213
Non-Qualified Stock Option Plans		9,987,200		8,567,808		N/A		1,167,166
Stock Bonus Plans		783,760		N/A		345,096		438,631
Stock Compensation Plans		634,000		N/A		150,695		464,895
Incentive Stock Bonus Plan		640,000		N/A		616,500		23,500

Table of Contents

Stock option activity:

	Three Months Ended December 31,
	2020		2019
Options granted		7,500		1,000
Options exercised		5,300		-
Options forfeited		42,166		-
Options expired		55		36

Stock-Based Compensation Expense

	Three months Ended December 31,
	2020		2019
Employees	$	3,296,309	$	1,800,225
Non-employees	$	248,660	$	155,740

Employee compensation expense includes the expense related to options and restricted stock granted expensed over their vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts.

Warrants and Non-Employee Options

The following chart represents the warrants and non-employee options outstanding at December 31, 2020:

Warrant/Options	Issue Date	Shares Issuable upon Exercise of Warrants/ Options		Exercise Price		Expiration Date	Reference
Series N	8/18/2008		85,339	$	3.00	8/18/2021		2
Series UU	6/11/2018		93,603	$	2.80	6/30/2021		2
Series X	1/13/2016		120,000	$	9.25	7/13/2021		2
Series Y	2/15/2016		26,000	$	12.00	8/15/2021		2
Series ZZ	5/23/2016		20,000	$	13.75	5/18/2021	*
Series BB	8/26/2016		16,000	$	13.75	8/22/2021	*
Series Z	5/23/2016		264,000	$	13.75	11/23/2021	*
Series FF	12/8/2016		68,048	$	3.91	12/1/2021	*
Series CC	12/8/2016		143,643	$	5.00	12/8/2021		1
Series HH	2/23/2017		200	$	3.13	2/16/2022	*
Series AA	8/26/2016		200,000	$	13.75	2/22/2022	*
Series MM	6/22/2017		797,633	$	1.86	6/22/2022	*
Series NN	7/24/2017		348,842	$	2.52	7/24/2022	*
Series RR	10/30/2017		417,649	$	1.65	10/30/2022	*
Series SS	12/19/2017		326,064	$	2.09	12/18/2022	*
Series TT	2/5/2018		361,564	$	2.24	2/5/2023		2
Consultants	7/28/2017 - 11/18/2020		15,000	$	2.18-11.61	11/17/2022 - 7/27/2027		3

* No current period changes to these warrants

Table of Contents

1.	Derivative Liabilities

The table below presents the fair value of the warrant liabilities at the balance sheet dates:

	December 31, 2020		September 30, 2020
Series W warrants	$	-	$	73,570
Series Z warrants		929,539		1,207,902
Series ZZ warrants		23,177		75,044
Series AA warrants		748,404		1,082,212
Series BB warrants		34,541		65,173
Series CC warrants		1,053,517		1,259,712
Series HH warrants		1,749		2,000
Total warrant liabilities	$	2,790,927	$	3,765,613

The table below presents the gains and (losses) on the warrant liabilities for the three months ended December 31:

	2020		2019
Series V warrants	$	-	$	555,031
Series W warrants		73,570		151,374
Series Z warrants		278,363		10,549
Series ZZ warrants		51,867		14,847
Series AA warrants		333,808		64,978
Series BB warrants		30,632		(431	)
Series CC warrants		164,345		(22,681	)
Series FF warrants		-		(7,189	)
Series HH warrants		251		(82	)
Series JJ warrants		-		(130	)
Series LL warrants		-		243
Net gain on warrant liabilities	$	932,836	$	766,509

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.

Changes in Warrant Liabilities

On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75 expired.

During the three months ended December 31, 2020, 5,000 Series CC warrants were exercised at an exercise price of $5.00 for gross proceeds of $25,000.

No warrants recorded as liabilities were exercised during the three months ended December 31, 2019.

2.	Equity Warrants

Changes in Equity Warrants

On December 7, 2020, the expiration date of the Series N warrants was extended six months from February 18, 2021 to August 18, 2021. The incremental cost of this extension was approximately $1,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series N warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.

Table of Contents

On December 7, 2020, the expiration date of the Series X warrants was extended six months from January 13, 2021 to July 13, 2021. The incremental cost of this extension was approximately $85,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series X warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.

On December 7, 2020, the expiration date of the Series Y warrants, which were issued in connection with a financing, was extended six months from February 15, 2021 to August 15, 2021. The incremental cost of this extension was approximately $41,000 and was recorded as additional paid-in capital.

On December 7, 2020, the expiration date of Series UU warrants were extended six months from December 31, 2020 to June 30, 2021. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was $192 and was recorded as interest expense for the three months ended December 31, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.

Exercise of Equity Warrants

During the three months ended December 31, 2020, 10,000 Series TT warrants were exercised at an exercise price of $2.24 for gross proceeds of $22,400.

The following warrants recorded as equity were exercised during the three months ended December 31, 2019.

Warrants	Warrants Exercised		Exercise Price		Proceeds
Series OO		10,000	$	2.52	$	25,200
Series SS		22,632	$	2.09		47,301
Series TT		100,628	$	2.24		224,600
		132,900			$	297,101

3.	Options and Shares Issued to Consultants

During the three months ended December 31, 2020 and 2019, the Company issued 15,044 and 15,819 shares of restricted common stock, respectively, to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $12.45 and $7.18, respectively, during the three months ended December 31, 2020 and 2019.

Additionally, during the three months ended December 31, 2020, the Company issued to a consultant 5,000 options to purchase common stock with an exercise price of $11.61. The options are exercisable beginning May 18, 2021 and expire on November 17, 2022. The options are being expensed on a straight-line basis over the six month vesting period at a fair value of approximately $28,000 or $5.65 per option. No options were issued to consultants during the three months ended December 31, 2019.

As of December 31, 2020 and September 30, 2020, 15,000 and 10,000 options issued to consultants remained outstanding, respectively, all of which were issued from the Non-Qualified Stock Option plans and of which 10,000 are vested as of the balance sheet dates.

During the three months ended December 31, 2020 and 2019, the Company recorded total expense of approximately $249,000 and $156,000, respectively, relating to these consulting agreements. At December 31, 2020 and September 30, 2020, approximately $244,000 and $395,000, respectively, are included in prepaid expenses.

Table of Contents

4.	Securities Purchase Agreement

During the three months ended December 31, 2020 and 2019, the Company realized approximately $0.1 million and $0.8 million, respectively, through the sale by Ergomed of 9,000 and 98,350 shares of the Company’s common stock and the Company reduced the payables to Ergomed, and credited Other Operating Gain by those amounts. No shares were issued to Ergomed during the quarters ended December 31, 2020 and 2019.

As of December 31, 2020, Ergomed held 93,521 shares for resale.

D.	FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

	·	Level 1 - Observable inputs such as quoted prices in active markets for identical assets or liabilities

	·	Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

	·	Level 3 - Unobservable inputs that reflect management’s assumptions

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of an input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2020:

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

2,790,927

Table of Contents

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2020:

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

3,765,613

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2020 and the year ended September 30, 2020:

	3 months ended December 31, 2020			12 months ended September 30, 2020

Beginning balance	$	3,765,613		$	6,488,310
Issuances		-			-
Exercises		(41,850	)		(3,071,775	)
Realized and unrealized (gains) and losses		(932,836	)		349,078
Ending balance	$	2,790,927		$	3,765,613

The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock, as well as U.S. Treasury Bill rates, are observable in active markets.

E.	RELATED PARTY TRANSACTIONS

On December 7, 2020, the expiration dates of the Series N and Series X warrants held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary, were extended by six months (Note C). The incremental cost of these modifications was approximately $86,000 and was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020.

On December 7, 2020, the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021. The incremental cost of this extension was $192 and was recorded as interest expense for the three months ended December 31, 2020. The Series UU warrants are held by certain officers of the Company and were originally issued with convertible debt.

F.	COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company’s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $34.0 million for Ergomed’s services. This amount is net of Ergomed’s discount of approximately $11.3 million. During the three months ended December 31, 2020 and 2019, the Company recorded, net of Ergomed’s discount, approximately $0.6 million and $0.9 million, respectively, as research and development expense related to Ergomed’s services.

Table of Contents

Lease Agreements

The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028.

On December 31, 2020 and September 30, 2020, the net book value of the finance lease right of use asset is approximately $13.4 million and $13.8 million, respectively and the balance of the finance lease liability is approximately $12.5 million and $12.7 million, respectively, of which approximately $1.0 million and $0.9 million, respectively, is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using a straight-line method over the underlying lease terms. Total cash paid related to finance leases during the each of the three months ended December 31, 2020 and 2019 was approximately $0.5 million, of which approximately $0.3 million was for interest. The weighted average discount rate of the Company’s finance leases is 8.8% and the weighted average time to maturity is 7.8 years.

In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The estimated cost of the upgrades is $10.5 million, of which approximately $6.7 million has been incurred to date. Pursuant to the amendment, the landlord agreed to finance the final $2.4 million of the costs incurred, i.e., after the Company has financed the initial $8.1 million. Per the terms of the financing, upon completion of the project, the $2.4 million will be repaid through increased lease payments over the remaining lease term.

The Company was required to deposit the equivalent of one year of base rent in accordance with the lease. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets at December 31, 2020 and September 30, 2020.

Approximate future minimum lease payments under finance leases as of December 31, 2020 are as follows:

Nine months ending September 30, 2021	$	1,469,000
Year ending September 30,
2022		2,014,000
2023		2,083,000
2024		2,148,000
2025		2,218,000
2026		2,294,000
Thereafter		5,028,000
Total future minimum lease obligation		17,254,000
Less imputed interest on finance lease obligations		(4,789,000	)
Net present value of lease finance lease obligations	$	12,465,000

Effective April 30, 2020, the Company terminated a month-to-month arrangement with a sub-lessee as the sub-leased space is needed to prepare the facility to produce Multikine for commercial purposes and before the Company’s Biologics License Application (BLA) can be submitted to the FDA. The sublease rental income for the three months ended December 31, 2019 was approximately $18,000.

Table of Contents

The Company leases two facilities under 60-month operating leases - the lease for its research and development laboratory expires February 28, 2022 and the lease for its office headquarters was renewed on July 1, 2020 and expires on November 30, 2025.The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the full 60-month terms of the leases. As of December 31, 2020 and September 30, 2020, the net book value of the operating lease right of use assets is approximately $1.2 million. As of December 31, 2020 and September 30, 2020, the balance of the operating lease liabilities is approximately $1.2 million and $1.3 million, respectively, of which approximately $0.2 million and $0.1 million, respectively, is current. The Company incurred lease expense for operating leases of approximately $66,000 and $68,000, respectively, for the three months ended December 31, 2020 and 2019. Total cash paid related to operating leases during the three months ended December 31, 2020 and 2019 was approximately $48,000 and $66,000, respectively.

As of December 31, 2020, future minimum lease payments on operating leases are as follows:

Nine months ending September 30, 2021	$	193,000
Year ending September 30,
2022		264,000
2022		272,000
2024		280,000
2025		288,000
2026		207,000
Thereafter		80,000
Total future minimum lease obligation		1,584,000
Less imputed interest on operating lease obligation		(354,000	)
Net present value of operating lease obligation	$	1,230,000

PATENTS

During the three months ended December 31, 2020 and 2019, no patent impairment charges were recorded. For both the three months ended December 31, 2020 and 2019, amortization of patent costs totaled approximately $13,000. Approximate estimated future amortization expense is as follows:

Nine months ending September 30, 2021	$	39,000
Year ending September 30,
2022		48,000
2023		38,000
2024		30,000
2025		27,000
2026		24,000
Thereafter		94,000
Total	$	300,000

H.	LOSS PER COMMON SHARE

The following tables provide the details of the basic and diluted loss per-share computations:

	Three months ended December 31,
	2020			2019
Loss per share - basic
Net loss available to common shareholders - basic	$	(8,022,643	)	$	(5,531,360	)
Weighted average shares outstanding - basic		38,670,247			35,084,279
Basic loss per common share	$	(0.21	)	$	(0.16	)

Loss per share - diluted
Net loss available to common shareholders - basic	$	(8,022,643	)	$	(5,531,360	)
Gain on derivatives (1)		(164,073	)		(243	)
Net loss available to common shareholders - diluted	$	(8,186,716	)	$	(5,531,603	)

Weighted average shares outstanding - basic		38,670,247			35,084,279
Incremental shares underlying dilutive - warrants and options (1)		97,039			14,329
Weighted average shares outstanding - diluted		38,767,286			35,098,608
Diluted loss earnings per common share	$	(0.21	)	$	(0.16	)

(1) Includes Series CC and HH warrants for the three months ended December 31, 2020 and Series LL warrants for the three months ended December 31, 2019.

The gain on derivatives priced lower than the average market price during the period is excluded from the numerator and the related shares are excluded from the denominator in calculating diluted loss per share.

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:

	2020		2019

Options and Warrants		6,517,160		7,009,959
Unvested Restricted Stock		302,500		304,500
Total		6,819,660		7,314,459

J.	SUBSEQUENT EVENTS

Between January 1, 2021 and February 5, 2021, the Company received approximately $3.9 million through the exercise of options and warrants to purchase shares of the Company’s common stock.

Table of Contents

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Liquidity and Capital Resources

The Company has fully enrolled 928 patients in a Phase 3 clinical trial for its lead investigational therapy, Multikine, in advanced primary head and neck cancer. This study was cleared by the U.S. FDA as well as twenty-three other countries. The pivotal Phase 3 study reached the targeted threshold of 298 events (deaths) required to conduct the data evaluation. The Company is now at the end of this 10-year-long study to prove this completely novel concept of activating the immune system to fight cancer before surgery, radiation and chemotherapy. The extensive database for the study was locked late last year (meaning it was ready to be analyzed) and experts are now analyzing the data according to a statistical analysis plan that was agreed to and finalized before database lock. The Company is blinded to the study data and is not involved in this process. The statistical analysis plan follows the protocol stated objectives and is designed to meet FDA requirements to define the clinical benefits that Multikine might provide for these patients. The analysis looks at multiple parameters to be able to gain the most information on the possible benefits of using Multikine immunotherapy before any other treatment in these patients. The Company will be advised of the results when the analysis is completed and the study results will be announced to the public at that time.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.

The Company also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System). The Company has product candidates under development for the potential treatment of rheumatoid arthritis and to potentially treat the COVID-19 coronavirus.

All the Company’s projects are under development. Consequently, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Since inception, the Company has financed its operations through the sale of equity securities, convertible notes, loans and certain research grants. The Company’s expenses will continue to exceed its revenues as it continues the development of Multikine and brings other drug candidates into clinical trials. Until the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist in funding the Company’s capital requirements.

Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, and the construction and upgrade of the Company’s manufacturing and laboratory facilities. The Company does not anticipate realizing significant revenues until entering into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all its liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $60.2 million as of December 31, 2020 on direct costs for the Phase 3 clinical trial and the filing of the clinical study report to the FDA. The Company estimates it will incur additional expenses of approximately $5.1 million for the remainder of the Phase 3 clinical trial. It should be noted that this estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug. This number may be affected by foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.

The Company uses two CRO’s to manage the global Phase 3 study; ICON and Ergomed, who are both international leaders in managing oncology trials.

Under a co-development agreement, Ergomed agreed to contribute up to $12 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount. Approximately $11.3 million of these credits were realized as of December 31, 2020.

During the three months ended December 31, 2020, the Company’s cash increased by approximately $6.4 million. Significant components of this increase include net proceeds from the sale of common stock and the exercise of warrants and options of approximately $13.6 million, offset by net cash used to fund the Company’s regular operations, including its Phase 3 clinical trial, of approximately $3.8 million, expenditures for leasehold improvements and equipment of approximately $3.2 million, and approximately $0.2 million in lease payments. During the three months ended December 31, 2019, the Company’s cash increased by approximately $0.9 million. Significant components of this increase include approximately $5.0 million in net proceeds from the sale of common stock in a public offering and the exercise of warrants of approximately $0.3 million, offset by net cash used to fund the Company’s regular operations, including its Phase 3 clinical trial, of approximately $4.1 million, approximately $0.1 million of equipment purchases and approximately $0.2 million in lease payments.

Table of Contents

The Company entered into a Securities Purchase Agreement with Ergomed plc, one of the Company’s Clinical Research Organizations responsible for managing the Company’s Phase 3 clinical trial, to facilitate a partial payment of amounts due Ergomed. Under the Agreement, the Company issued Ergomed shares of common stock that the net proceeds from the sales of those shares would reduce outstanding amounts due Ergomed. Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale of the Company’s shares by Ergomed and reduces accounts payable to Ergomed. During the quarters ended December 31, 2020 and 2019, the Company realized approximately $0.1 million and $0.8 million, respectively, through the sale by Ergomed of 9,000 and 98,350 shares of the Company’s common stock and the Company reduced accounts payable to Ergomed and credited Other operating gains by those amounts.

Prepaid expenses decreased by approximately $0.7 million, or 52%, at December 31, 2020 as compared to September 30, 2020 due to the utilization of amounts paid in advance to the Company’s CRO.

During the three months ended December 31, 2020, supplies used for R&D and manufacturing increased by approximately $0.3 million, or 41%, as compared to September 30, 2020 due to support of the work on modifications of the manufacturing facility in order to prepare the facility to produce Multikine for commercial purposes and before the Company’s Biologics License Application (BLA) can be submitted to the FDA.

During the three months ended December 31, 2020, the Company incurred approximately $3.6 million in costs to upgrade its manufacturing facility to prepare for the potential commercial production of Multikine. Total estimated costs of this upgrade are approximately $10.5 million, of which approximately $6.7 million has been incurred to date. The landlord of the property has contingently agreed to finance the final $2.4 million of costs and allow for the repayment through increased lease payments upon completion of the project. Upon completion of these upgrades and the finalization of costs and timing of the upgrades, the Company expects to enter into an amendment to the lease which would include an increase to the monthly lease payments and the effective interest rate.

Results of Operations and Financial Condition

During the three months ended December 31, 2020, research and development expenses increased by approximately $1.2 million, or 27%, compared to the three months ended December 31, 2019. Major components of this increase include approximately $0.6 million in expenses related to the Phase 3 clinical study and approximately $0.7 million in employee stock compensation expense, of which $0.4 million relates to the 2020 Non-Qualified Stock Option Plan. These increases were offset by a net decrease of approximately $0.1 million in other research and development costs.

During the three months ended December 31, 2020, general and administrative expenses increased by approximately $0.7 million, or 26%, compared to the three months ended December 31, 2019. A major component of the increase is an approximate $0.8 million increase in employee stock compensation costs relating to the 2020 Non-Qualified Stock Option Plan, offset by approximately $0.1 million net decrease in other general and administrative costs.

During the three months ended December 31, 2020 and 2019, the Company recorded derivative gains of approximately $0.9 million and $0.8 million, respectively. This variation was the result of the change in fair value of the derivative liabilities during the period which was caused by fluctuations in the share price of CEL-SCI’s common stock.

Net interest expense remained relatively constant at approximately $0.3 million for both the three months ended December 31, 2020 and December 31, 2019.

Research and Development Expenses

The Company’s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.

Table of Contents

	Three months ended December 31,
	2020		2019

MULTIKINE	$	5,011,950	$	4,012,644
LEAPS		402,810		240,169

TOTAL	$	5,414,760	$	4,252,813

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Critical Accounting Estimates and Policies

Management’s discussion and analysis of the Company’s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of operating leases and stock-based compensation. For more information regarding the Company’s critical accounting estimates and policies, see Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended September 30, 2020. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company’s Board of Directors.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

The Company does not believe that it has any significant exposures to market risk.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company’s management, including the Company’s Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of December 31, 2020. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective as of December 31, 2020.

Table of Contents

Management’s Report on Internal Control over Financial Reporting

CEL-SCI’s management is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the Securities and Exchange Commission, internal control over financial reporting is a process designed by, or under the supervision of CEL-SCI’s Chief Executive and Principal Financial and Accounting Officer and implemented by CEL-SCI’s Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of CEL-SCI’s financial statements in accordance with U.S. generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of management, including CEL-SCI’s Chief Executive and Principal Financial and Accounting Officer, CEL-SCI evaluated the effectiveness of its internal control over financial reporting as of December 31, 2020 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or the COSO Framework. Management’s assessment included an evaluation of the design of CEL-SCI’s internal control over financial reporting and testing of the operational effectiveness of those controls. Due to the material weaknesses noted below, CEL-SCI's Chief Executive and Principal Financial and Accounting Officer concluded that as of such date, CEL-SCI's internal control over financial reporting was not effective.

Material Weaknesses in Internal Control Over Financial Reporting

When calculating the right of use (ROU) asset under ASC 842 during the preparation of the year-end financial statements, CEL-SCI determined that the opening finance ROU asset and total stockholders’ equity balances were understated by approximately $2.04 million as of October 1, 2019, the date of adoption. The changes do not impact any prior year’s financial statements but are an adjustment to the opening finance ROU asset and accumulated deficit balances effective October 1, 2019. As a result of the changes to the opening finance ROU asset and accumulated deficit balances, the financial statements filed for the quarter ended December 31, 2019 were restated. The failure to properly value the finance ROU asset as of October 1, 2019 under ASC 842 is a control deficiency that constitutes a material weakness.

In order to remediate this material weakness, CEL-SCI will change certain control activities over financial reporting to include the following:

	·	CEL-SCI will thoroughly review all leases against the guidance in ASC 842.
	·	CEL-SCI will engage additional outside financial reporting specialists to assist in the review process.
	·	CEL-SCI will provide additional training for those involved in the review process of new leases.

CEL-SCI is committed to maintaining a strong internal control environment and implementing measures designed to help ensure that control deficiencies contributing to the material weaknesses are remediated as soon as possible.

Changes in Internal Control over Financial Reporting

There were no other changes in the Company’s internal control over financial reporting that occurred during the quarter ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

PART II

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the three months ended December 31, 2020 the Company issued 15,819 restricted shares of common stock to consultants for investor relations services.

The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company’s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.

Item 6. Exhibits

Number		Exhibit

31		Rule 13a-14(a) Certifications

32		Section 1350 Certifications

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CEL-SCI CORPORATION

Date: February 12, 2021	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer*

* Also signing in the capacity of the Principal Accounting and Financial Officer.

EX-31 2 cvm_ex31.htm CERTIFICATIONS cvm_ex31.htm

EXHIBIT 31

CERTIFICATIONS

I, Geert Kersten, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.


February 12, 2021	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer

CERTIFICATIONS

I, Geert Kersten, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.


February 12, 2021	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Financial Officer

EX-32 3 cvm_ex32.htm IN CONNECTION WITH THE QUARTERLY REPORT OF CEL-SCI CORPORATION (THE COMPANY ) ON FORM 10-Q FOR THE PERIOD ENDING DECEMBER 31, 2020 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE REPORT ), GEERT KERSTEN, THE CHIEF EXECUTIVE AND PRINCIPAL AND OF cvm_ex32.htm

EXHIBIT 32

In connection with the Quarterly Report of CEL-SCI Corporation (the “Company”) on Form 10-Q for the period ending December 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), Geert Kersten, the Chief Executive and Principal Financial and Accounting Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.

By:

/s/ Geert Kersten

Geert Kersten

Chief Executive and

Principal Financial and Accounting Officer

February 12, 2021

EX-101.SCH 4 cvm-20201231.xsd XBRL SCHEMA FILE 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - OPERATIONS AND FINANCING link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - PATENTS link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - PATENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - A BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - C STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - C STOCKHOLDERS EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - C STOCKHOLDERS EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - C STOCKHOLDERS EQUITY (Details 3) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - C STOCKHOLDERS EQUITY (Details 4) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - C STOCKHOLDERS EQUITY (Details 5) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - C STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - D FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - D FAIR VALUE MEASUREMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - ERELATED PARTY TRANSACTIONS (Details Narrative ) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - F COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - F COMMITMENTS AND CONTINGENCIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - F COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - G PATENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - G PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - H LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - H LOSS PER COMMON SHARE (Details 1) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - J SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 cvm-20201231_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 cvm-20201231_def.xml XBRL DEFINITION FILE EX-101.LAB 7 cvm-20201231_lab.xml XBRL LABEL FILE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Entity Interactive Data Current CONDENSED BALANCE SHEETS ASSETS Current Assets: Cash and cash equivalents Receivables Prepaid expenses Supplies used for R&D and manufacturing Total current assets [Assets, Current] Finance lease right of use assets Operating lease right of use assets Property and equipment, net Patent costs, net Deposits Total Assets [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable Accrued expenses Due to employees Derivative instruments, current portion Lease liabilities, current portion Total current liabilities [Liabilities, Current] Derivative instruments, net of current portion Finance lease obligations, net of current portion Operating lease obligations, net of current portion Other liabilities Total liabilities [Liabilities] Commitments and Contingencies STOCKHOLDERS' EQUITY Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding Common stock, $.01 par value - 600,000,000 shares authorized; 39,767,058 and 38,730,150 shares issued and outstanding at December 31, 2020 and September 30, 2020, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Grant income Operating Expenses: Research and development General and administrative Total operating expenses [Operating Expenses] Operating loss [Operating Income (Loss)] Other income Gain on derivative instruments Other non-operating gains Interest expense, net Net loss [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Modification of warrants Net loss available to common shareholders [Net Income (Loss) Available to Common Stockholders, Basic] Net loss per common share BASIC DILUTED Weighted average common shares outstanding BASIC [Weighted Average Number of Shares Outstanding, Basic] DILUTED [Weighted Average Number of Shares Outstanding, Diluted] STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Statement [Table] Statement [Line Items] Statement Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Adoption of new accounting standard Issuance of common stock, shares Issuance of common stock, amount Warrant exercises, shares Warrant exercises, amount Equity based compensation - employees, amount 401(k) contributions paid in common stock, shares 401(k) contributions paid in common stock, amount Stock issued to nonemployees for service, shares Stock issued to nonemployees for service, amount Purchase of stock by officer, shares Purchase of stock by officer, amount Share issuance costs Net loss [Net Income (Loss) Attributable to Parent] Proceeds from the sale of common stock, shares Proceeds from the sale of common stock, amount Equity based compensation - employees, shares Option exercises, shares Option exercises, amount Modification of warrants [Modification of warrants] Balance, shares Balance, amount CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Share-based payments for services Equity based compensation Common stock contributed to 401(k) plan Gain on derivative instruments [Gain (Loss) on Sale of Derivatives] Modification of warrants [Modification of warrants 1] (Increase)/decrease in assets: Receivables [Increase (Decrease) in Receivables] Prepaid expenses [Increase (Decrease) in Prepaid Expense] Supplies used for R&D and manufacturing [Supplies used for R&D and manufacturing] Increase/(decrease) in liabilities: Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Due to employees [Increase (Decrease) in Due to Officers and Stockholders] Other liabilities [Increase (Decrease) in Other Operating Liabilities] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment [Payments to Acquire Property, Plant, and Equipment] Proceeds from the sale of equipment Expenditures for patent costs [Payments to Acquire Intangible Assets] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock Payments of stock issuance costs [Payments of Stock Issuance Costs] Proceeds from the purchase of stock by officer Proceeds from exercises of warrants and options Payments on obligations under finance lease [Finance Lease, Principal Payments] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] NET INCREASE IN CASH AND CASH EQUIVALENTS [Cash and Cash Equivalents, Period Increase (Decrease)] CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Property and equipment included in current liabilities Capitalizable patent costs included in current liabilities Finance lease obligation included in accounts payable Prepaid consulting services paid with issuance of common stock Exercise of derivative liabilities Financing costs included in current liabilities Cash paid for interest BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OPERATIONS AND FINANCING B. OPERATIONS AND FINANCING STOCKHOLDERS EQUITY C. STOCKHOLDERS' EQUITY FAIR VALUE MEASUREMENTS D. FAIR VALUE MEASUREMENTS RELATED PARTY TRANSACTIONS E. RELATED PARTY TRANSACTIONS COMMITMENTS AND CONTINGENCIES EX-101.PRE 8 cvm-20201231_pre.xml XBRL PRESENTATION FILE XML 9 cvm_10q_htm.xml IDEA: XBRL DOCUMENT 0000725363 2020-10-01 2020-12-31 0000725363 us-gaap:SubsequentEventMember 2021-01-01 2021-02-05 0000725363 us-gaap:RestrictedStockMember 2019-10-01 2019-12-31 0000725363 us-gaap:RestrictedStockMember 2020-10-01 2020-12-31 0000725363 us-gaap:OptionMember 2019-10-01 2019-12-31 0000725363 us-gaap:OptionMember 2020-10-01 2020-12-31 0000725363 cvm:ErgomedMember 2019-10-01 2019-12-31 0000725363 cvm:ErgomedMember 2020-10-01 2020-12-31 0000725363 cvm:LeaseAgreementMember 2020-08-01 2020-08-31 0000725363 cvm:LandlordMember 2020-08-01 2020-08-31 0000725363 2018-10-01 2019-09-30 0000725363 2018-09-30 0000725363 us-gaap:FairValueInputsLevel2Member 2020-09-30 0000725363 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000725363 us-gaap:FairValueInputsLevel3Member 2020-09-30 0000725363 us-gaap:FairValueInputsLevel3Member 2020-12-31 0000725363 us-gaap:FairValueInputsLevel1Member 2020-09-30 0000725363 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000725363 us-gaap:RestrictedStockMember cvm:ConsultantsMember 2019-10-01 2019-12-31 0000725363 us-gaap:RestrictedStockMember cvm:ConsultantsMember 2020-10-01 2020-12-31 0000725363 cvm:ConsultingAgreementsMember 2019-10-01 2019-12-31 0000725363 cvm:ConsultingAgreementsMember 2020-10-01 2020-12-31 0000725363 cvm:ConsultantsMember 2020-10-01 2020-12-31 0000725363 cvm:SPAMember cvm:ErgomedMember 2019-12-31 0000725363 cvm:SPAMember cvm:ErgomedMember 2020-12-31 0000725363 cvm:ErgomedMember 2019-12-31 0000725363 cvm:ErgomedMember 2020-12-31 0000725363 cvm:SeriesWWarrantsMember 2020-06-01 2020-06-25 0000725363 cvm:SeriesWWarrantsMember 2020-06-25 0000725363 cvm:NonQualifiedOptionsPlanMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesNWarrantsMember 2020-12-01 2020-12-07 0000725363 cvm:SeriesNWarrantsMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesUUWarrantsMember 2020-12-01 2020-12-07 0000725363 cvm:SeriesUUWarrantsMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesXMember 2020-12-01 2020-12-07 0000725363 cvm:SeriesYMember 2020-12-01 2020-12-07 0000725363 cvm:ConsultantsOneMember 2020-09-01 2020-09-30 0000725363 cvm:ConsultantsOneMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesTTMember 2019-10-01 2019-12-31 0000725363 cvm:SeriesSSMember 2019-10-01 2019-12-31 0000725363 cvm:SeriesOOMember 2019-10-01 2019-12-31 0000725363 cvm:SeriesTTMember 2020-12-31 0000725363 cvm:SeriesTTMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesSSMember 2020-12-31 0000725363 cvm:SeriesSSMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesRRMember 2020-12-31 0000725363 cvm:SeriesRRMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesNNMember 2020-12-31 0000725363 cvm:SeriesNNMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesMmMember 2020-12-31 0000725363 cvm:SeriesMmMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesAaMember 2020-12-31 0000725363 cvm:SeriesAaMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesHhMember 2020-12-31 0000725363 cvm:SeriesHhMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesCcMember 2020-12-31 0000725363 cvm:SeriesCcMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesFFMember 2020-12-31 0000725363 cvm:SeriesFFMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesZMember 2020-12-31 0000725363 cvm:SeriesZMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesBBMember 2020-12-31 0000725363 cvm:SeriesBBMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesZZMember 2020-12-31 0000725363 cvm:SeriesZZMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesYMember 2020-12-31 0000725363 cvm:SeriesYMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesXMember 2020-12-31 0000725363 cvm:SeriesXMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesUUMember 2020-10-01 2020-12-31 0000725363 cvm:SeriesUUMember 2020-12-31 0000725363 cvm:SeriesNMember 2020-12-31 0000725363 cvm:SeriesNMember 2020-10-01 2020-12-31 0000725363 srt:MaximumMember cvm:ConsultantsMember 2020-12-31 0000725363 srt:MaximumMember cvm:ConsultantsMember 2020-10-01 2020-12-31 0000725363 srt:MinimumMember cvm:ConsultantsMember 2020-10-01 2020-12-31 0000725363 srt:MinimumMember cvm:ConsultantsMember 2020-12-31 0000725363 cvm:ConsultantsMember 2020-12-31 0000725363 cvm:IncentiveStockBonusPlansMember 2020-09-30 0000725363 cvm:IncentiveStockBonusPlansMember 2020-12-31 0000725363 us-gaap:StockCompensationPlanMember 2020-09-30 0000725363 us-gaap:StockCompensationPlanMember 2020-12-31 0000725363 cvm:StockBonusPlansMember 2020-09-30 0000725363 cvm:StockBonusPlansMember 2020-12-31 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2020-09-30 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2020-12-31 0000725363 cvm:IncentiveStockOptionPlansMember 2020-09-30 0000725363 cvm:IncentiveStockOptionPlansMember 2020-12-31 0000725363 us-gaap:PatentsMember 2020-10-01 2020-12-31 0000725363 us-gaap:RetainedEarningsMember 2020-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000725363 us-gaap:CommonStockMember 2020-12-31 0000725363 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0000725363 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0000725363 us-gaap:RetainedEarningsMember 2020-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000725363 us-gaap:CommonStockMember 2020-09-30 0000725363 2019-12-31 0000725363 us-gaap:RetainedEarningsMember 2019-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000725363 us-gaap:CommonStockMember 2019-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0000725363 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000725363 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000725363 2019-09-30 0000725363 us-gaap:RetainedEarningsMember 2019-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000725363 us-gaap:CommonStockMember 2019-09-30 0000725363 2019-10-01 2019-12-31 0000725363 2020-09-30 0000725363 2020-12-31 0000725363 2021-02-05 iso4217:USD shares iso4217:USD shares pure 0000725363 false --09-30 false Q1 2021

0.01

200000

0.01

600000000

38730150

39767058

1700000

500000 300000 1200000

13000

10-Q true 2020-12-31 false 001-11889 CEL-SCI CORPORATION CO 84-0916344 8229 Boone Boulevard Suite 802 Vienna VA 22182 703 506-9460 Common Stock CVM NYSE Yes Yes Non-accelerated Filer true false 40529278

21860482

15508909

54922

629894

1313432

1152837

820052

23698135

17697315

13382401

13811849

1160305

1198958

9401891

5843993

300356

313422

1670917

49614005

40536454

3092856

2023067

616163

510515

458740

448022

2040773

213787

1125337 1070123

7333869

4265514

750154

3551826

11495840

11753100

1073470

1114340

125000

20778333

20809780

0.01

200000

0.01

600000000

39767058

38730150

397671

387302

418210168

401174675

-389772167

-381835303

28835672

19726674

49614005

40536454

35506

5414760

4252813

3316156

2638896

8730916

6891709

-8730916

-6856203

18448

932836

766509

121606

790669

-260390

-250783

-7936864

-5531360

-85779 0

-8022643

-5531360

-0.21

-0.16

-0.21

-0.16

38670247

35084279

38767286

35098608

38730150

387302

401174675

-381835303

19726674

1000000 10000 13549500 0 13559500 15000 150 89100 0 89250 -2000 -20 3296329 0 3296309

3564

41635

41671

15044

150

152300

152450

5300

23458

23511

0 192 0 192 0 -117021 0 -117021

-7936864

39767058

397671

418210168

-389772167

28835672

35231776

352318

358507603

-353726254

5133667

2146195 2146195

606395

6064

5043939

5050003

132900 1329 295772 0 297101 0 1800225 0 1800225

4474

40892

40937

15819

158

84289

84447

3725

24963

25000

0 -92150 0 -92150

-5531360

35995089

359951

365705533

-357111419

8954065

-7936864

-5531360

550682

502540

248660

155740

3296309

1800225

41671 40937

-932836

-766509

192 0

532328

-28278

-332785

86567

0 -123512

532679

-393064

143028

80432

10718

76520

18319

-1914

-3827899

-4101676

3149820

101820

4500

12390

-3149820

-109710

13559500

5050003

79499

31080

25000

70911

297101

221620

191034

13329292

5149990

6351573

938604

15508909

8444774

21860482

9383378

1700969 296941 15000 0 1752 745 243687 -71293 41850 0 88021 76650

277618

295107

Property and Equipment - Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

P17Y

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Leases - The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment, over a period of time, in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. For purposes of calculating lease liabilities, lease and non-lease components are combined.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2020 and September 30, 2020.

Derivative Instruments - The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim reporting period.

Stock-Based Compensation - Compensation cost for stock-based awards to employees and non-employees is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation - Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s common stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Vesting of restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Newly Adopted Accounting Pronouncements In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement - Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820).” Under the new standard, the amount and reason for a transfer between Level 1 and Level 2 of the fair value hierarchy is no longer required to be disclosed, but public companies are required to disclose a range and weighted average of significant unobservable inputs for Level 3 fair value measurements. The Company adopted the new standard on July 1, 2020 with no impact to the Company’s financial statements. New Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted. All of the Company’s liability classified warrants will be expired by that date and the Company does not expect the adoption to have a significant impact on its financial statements. The effect, if any, will largely depend on the composition and terms of the financial instruments at the time of adoption. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

<table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">C. </td><td style="vertical-align:top;">STOCKHOLDERS’ EQUITY</td></tr></tbody></table> Proceeds from the Sale of Common Stock In December 2020, the Company sold 1,000,000 shares of common stock at a public offering price of $14.65 per share and received aggregate proceeds of approximately $13.6 million. Under the terms of the Underwriting Agreement the Company granted the Underwriters a 30-day option to purchase up to an additional 150,000 shares of common stock at the public offering price to cover over-allotments. Equity Compensation Underlying share information for equity compensation plans as of December 31, 2020 is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Name of Plan</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total Shares Reserved Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Reserved for Outstanding Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issued</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Remaining Options/Shares Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Options Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,895</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-Qualified Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,987,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,527,787</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,201,832</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock Bonus Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,660</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">435,067</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock Compensation Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,695</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,895</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Bonus Plan</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Underlying share information for equity compensation plans as of September 30, 2020 is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Name of Plan</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total Shares Reserved Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Reserved for Outstanding Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issued</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Remaining Options/Shares Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,895</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-Qualified Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,987,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,567,808</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,167,166</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock Bonus Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">345,096</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">438,631</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock Compensation Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,695</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,895</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Bonus Plan</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">616,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,500</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>Stock option activity: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;">Three Months Ended December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,166</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Stock-Based Compensation Expense <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;">Three months Ended December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,296,309</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,800,225</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">248,660</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">155,740</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Employee compensation expense includes the expense related to options and restricted stock granted expensed over their vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. Warrants and Non-Employee Options The following chart represents the warrants and non-employee options outstanding at December 31, 2020: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrant/Options</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Issue Date</td><td style="BORDER-BOTTOM: black 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issuable upon Exercise of Warrants/ Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiration Date</td><td style="BORDER-BOTTOM: black 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Reference</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series N</td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2008</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2021 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series UU</td><td style="width:1%;white-space: nowrap;"> </td><td>6/11/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/30/2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series X</td><td style="width:1%;white-space: nowrap;"> </td><td>1/13/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/13/2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Y</td><td style="width:1%;white-space: nowrap;"> </td><td>2/15/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/15/2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series ZZ</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>5/18/2021</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series BB</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/22/2021</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/23/2021</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series FF</td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,048</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.91</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/1/2021</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">143,643</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH</td><td style="width:1%;white-space: nowrap;"> </td><td>2/23/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/16/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/22/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">797,633</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,842</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2"> *</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">417,649</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td>12/19/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">326,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/18/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">361,564</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Consultants</td><td style="width:1%;white-space: nowrap;"> </td><td>7/28/2017 - 11/18/2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="vertical-align:top;">$</td><td style="vertical-align:top;"> 2.18-11.61</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/17/2022 - 7/27/2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> * No current period changes to these warrants<table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">1. </td><td style="vertical-align:top;">Derivative Liabilities</td></tr></tbody></table> The table below presents the fair value of the warrant liabilities at the balance sheet dates: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series W warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">929,539</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,207,902</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series ZZ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,177</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">75,044</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">748,404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,082,212</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series BB warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34,541</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,053,517</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,259,712</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,749</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total warrant liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,790,927</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The table below presents the gains and (losses) on the warrant liabilities for the three months ended December 31: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series V warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">555,031</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series W warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,374</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">278,363</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,549</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series ZZ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,867</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,847</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,808</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,978</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series BB warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,632</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(431</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,345</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(22,681</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series FF warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,189</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(82</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series JJ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(130</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series LL warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">243</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net gain on warrant liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">932,836</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">766,509</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded. In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss. Changes in Warrant Liabilities On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75 expired. During the three months ended December 31, 2020, 5,000 Series CC warrants were exercised at an exercise price of $5.00 for gross proceeds of $25,000. No warrants recorded as liabilities were exercised during the three months ended December 31, 2019. <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">2. </td><td style="vertical-align:top;">Equity Warrants</td></tr></tbody></table> Changes in Equity Warrants On December 7, 2020, the expiration date of the Series N warrants was extended six months from February 18, 2021 to August 18, 2021. The incremental cost of this extension was approximately $1,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series N warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.On December 7, 2020, the expiration date of the Series X warrants was extended six months from January 13, 2021 to July 13, 2021. The incremental cost of this extension was approximately $85,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2020. The Series X warrants are held by the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary. On December 7, 2020, the expiration date of the Series Y warrants, which were issued in connection with a financing, was extended six months from February 15, 2021 to August 15, 2021. The incremental cost of this extension was approximately $41,000 and was recorded as additional paid-in capital. On December 7, 2020, the expiration date of Series UU warrants were extended six months from December 31, 2020 to June 30, 2021. These warrants were previously issued as an inducement to convert notes payable into shares of common stock. The incremental cost of this extension was $192 and was recorded as interest expense for the three months ended December 31, 2020. The Series UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary. Exercise of Equity Warrants During the three months ended December 31, 2020, 10,000 Series TT warrants were exercised at an exercise price of $2.24 for gross proceeds of $22,400. The following warrants recorded as equity were exercised during the three months ended December 31, 2019. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">ExercisePrice</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Proceeds</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series OO</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,632</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47,301</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">100,628</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">224,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">132,900</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">297,101</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">3. </td><td style="vertical-align:top;">Options and Shares Issued to Consultants</td></tr></tbody></table> During the three months ended December 31, 2020 and 2019, the Company issued 15,044 and 15,819 shares of restricted common stock, respectively, to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $12.45 and $7.18, respectively, during the three months ended December 31, 2020 and 2019. Additionally, during the three months ended December 31, 2020, the Company issued to a consultant 5,000 options to purchase common stock with an exercise price of $11.61. The options are exercisable beginning May 18, 2021 and expire on November 17, 2022. The options are being expensed on a straight-line basis over the six month vesting period at a fair value of approximately $28,000 or $5.65 per option. No options were issued to consultants during the three months ended December 31, 2019. As of December 31, 2020 and September 30, 2020, 15,000 and 10,000 options issued to consultants remained outstanding, respectively, all of which were issued from the Non-Qualified Stock Option plans and of which 10,000 are vested as of the balance sheet dates. During the three months ended December 31, 2020 and 2019, the Company recorded total expense of approximately $249,000 and $156,000, respectively, relating to these consulting agreements. At December 31, 2020 and September 30, 2020, approximately $244,000 and $395,000, respectively, are included in prepaid expenses. <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;">4. </td><td style="vertical-align:top;">Securities Purchase Agreement</td></tr></tbody></table> The Company entered into a Securities Purchase Agreement with Ergomed plc, one of the Company’s Clinical Research Organizations responsible for managing the Company’s Phase 3 clinical trial, to facilitate payment of amounts due to Ergomed. Under the Agreement, the Company issued Ergomed shares of common stock that the net proceeds from the sales of those shares would reduce outstanding amounts due Ergomed. Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed. During the three months ended December 31, 2020 and 2019, the Company realized approximately $0.1 million and $0.8 million, respectively, through the sale by Ergomed of 9,000 and 98,350 shares of the Company’s common stock and the Company reduced the payables to Ergomed, and credited Other Operating Gain by those amounts. No shares were issued to Ergomed during the quarters ended December 31, 2020 and 2019. As of December 31, 2020, Ergomed held 93,521 shares for resale.

1000000

14.65

13600000

150000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Name of Plan</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total Shares Reserved Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Reserved for Outstanding Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issued</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Remaining Options/Shares Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Options Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,895</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-Qualified Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,987,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,527,787</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,201,832</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock Bonus Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,660</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">435,067</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock Compensation Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,695</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,895</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Bonus Plan</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Underlying share information for equity compensation plans as of September 30, 2020 is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Name of Plan</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total Shares Reserved Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Reserved for Outstanding Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issued</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Remaining Options/Shares Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,895</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-Qualified Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,987,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,567,808</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,167,166</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock Bonus Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">345,096</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">438,631</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock Compensation Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,695</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,895</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Bonus Plan</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">616,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,500</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

138400

85895

213

9987200

8527787

1201832

783760

348660

435067

634000

150695

464895

640000

614500

25500

138400

85895

213

9987200

8567808

1167166

783760

345096

438631

634000

150695

464895

640000

616500

23500

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;">Three Months Ended December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,166</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

7500

1000

5300

42166

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;">Three months Ended December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,296,309</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,800,225</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">248,660</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">155,740</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

3296309

1800225

248660 155740 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrant/Options</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Issue Date</td><td style="BORDER-BOTTOM: black 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares Issuable upon Exercise of Warrants/ Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expiration Date</td><td style="BORDER-BOTTOM: black 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Reference</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series N</td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2008</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/18/2021 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series UU</td><td style="width:1%;white-space: nowrap;"> </td><td>6/11/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/30/2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series X</td><td style="width:1%;white-space: nowrap;"> </td><td>1/13/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/13/2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Y</td><td style="width:1%;white-space: nowrap;"> </td><td>2/15/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/15/2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series ZZ</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>5/18/2021</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series BB</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>8/22/2021</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z</td><td style="width:1%;white-space: nowrap;"> </td><td>5/23/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/23/2021</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series FF</td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,048</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.91</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/1/2021</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC</td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">143,643</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/8/2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH</td><td style="width:1%;white-space: nowrap;"> </td><td>2/23/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/16/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA</td><td style="width:1%;white-space: nowrap;"> </td><td>8/26/2016</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/22/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series MM</td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">797,633</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6/22/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series NN</td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">348,842</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7/24/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2"> *</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series RR</td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">417,649</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>10/30/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td>12/19/2017</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">326,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>12/18/2022</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">*</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">361,564</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2/5/2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Consultants</td><td style="width:1%;white-space: nowrap;"> </td><td>7/28/2017 - 11/18/2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="vertical-align:top;">$</td><td style="vertical-align:top;"> 2.18-11.61</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>11/17/2022 - 7/27/2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 8/18/2008 85339 3.00 8/18/2021 6/11/2018 93603 2.80 6/30/2021 1/13/2016 120000 9.25 7/13/2021 2/15/2016 26000 12.00 8/15/2021 5/23/2016 20000 13.75 5/18/2021 8/26/2016 16000 13.75 8/22/2021 5/23/2016 264000 13.75 11/23/2021 12/8/2016 68048 3.91 12/1/2021 12/8/2016 143643 5.00 12/8/2021 2/23/2017 200 3.13 2/16/2022 8/26/2016 200000 13.75 2/22/2022 6/22/2017 797633 1.86 6/22/2022 7/24/2017 348842 2.52 7/24/2022 10/30/2017 417649 1.65 10/30/2022 12/19/2017 326064 2.09 12/18/2022 2/5/2018 361564 2.24 2/5/2023 7/28/2017 11/18/2020 15000 2.18 11.61 11/17/2022 7/27/2027 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series W warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">929,539</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,207,902</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series ZZ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,177</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">75,044</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">748,404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,082,212</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series BB warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34,541</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series CC warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,053,517</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,259,712</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,749</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total warrant liabilities </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,790,927</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 0 73570 929539 1207902 23177 75044 748404 1082212 34541 65173 1053517 1259712 1749 2000 2790927 3765613 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series V warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">555,031</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series W warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,374</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">278,363</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,549</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series ZZ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,867</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,847</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,808</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,978</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series BB warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,632</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(431</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,345</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(22,681</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series FF warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,189</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series HH warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(82</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series JJ warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(130</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series LL warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">243</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net gain on warrant liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">932,836</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">766,509</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 0 555031 73570 151374 278363 10549 51867 14847 333808 64978 30632 -431 164345 -22681 0 -7189 251 -82 0 -130 0 243

932836

766509

688930

16.75

5000 5.00

25000

the expiration date of the Series N warrants was extended six months from February 18, 2021 to August 18, 2021

1000

the expiration date of the Series X warrants was extended six months from January 13, 2021 to July 13, 2021

85000

41000

the expiration date of Series UU warrants were extended six months from December 31, 2020 to June 30, 2021

192

10000 2.24

22400

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Warrants</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants Exercised</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">ExercisePrice</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"> Proceeds</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series OO</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series SS</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,632</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47,301</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series TT</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">100,628</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">224,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">132,900</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">297,101</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 10000 2.52 25200 22632 2.09 47301 100628 2.24 224600 132900 297101

15044

15819

12.45

7.18

5000

11.61

November 17, 2022

28000

5.65

15000 10000

10000

249000

156000

244000 395000

100000

800000

9000

98350

93521

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant Other Observable Inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant Unobservable Inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative instruments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,790,927</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,790,927</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quoted Prices in Active Markets for Identical Assets or Liabilities(Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant Other Observable Inputs(Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant Unobservable Inputs(Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative instruments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

2790927

3765613

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">3 months ended December 31, 2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">12 months ended September 30, 2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Beginning balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,488,310</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(41,850</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,071,775</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Realized and unrealized (gains) and losses</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(932,836</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">349,078</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,790,927</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

3765613

6488310

-41850

-3071775

-932836 349078

2790927

3765613

86000

the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021

192

12000000

34000000.0

11300000

600000

900000

The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028

13400000 13800000

12500000

12700000

1000000.0 900000 500000 300000

0.088

P7Y9M18D 10500000 6700000 2400000 8100000 2400000

1700000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Nine months ending September 30, 2021 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,469,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,014,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,083,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,148,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,218,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,294,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,028,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum lease obligation </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,254,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest on finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,789,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net present value of lease finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">12,465,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Nine months ending September 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">193,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">272,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">280,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">288,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">207,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">80,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest on operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(354,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net present value of operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,230,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1469000

2014000

2083000

2148000

2218000

2294000

5028000

17254000

-4789000

12465000

18000

1200000

1300000

200000

100000

66000

68000

48000

66000

193000

264000

272000

280000

288000

207000

80000

1584000

-354000

1230000

13000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Nine months ending September 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">94,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

39000

48000

38000

30000

27000

24000

94000

300000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td> </td><td colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three months ended December 31,</td><td> </td></tr><tr style="height:15px"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: -15px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Loss per share - basic</td><td style="width:1%;"> </td><td colspan="2" style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td colspan="2" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss available to common shareholders - basic</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,022,643</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,531,360</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding - basic</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">38,670,247</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">35,084,279</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic loss per common share</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.21</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.16</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss per share - diluted</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss available to common shareholders - basic</td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">(8,022,643</td><td style="width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">(5,531,360</td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gain on derivatives (1)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(164,073</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(243</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss available to common shareholders - diluted</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,186,716</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,531,603</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding - basic</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">38,670,247</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">35,084,279</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incremental shares underlying dilutive - warrants and options (1)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">97,039</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,329</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding - diluted</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">38,767,286</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">35,098,608</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted loss earnings per common share</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.21</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.16</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr></tbody></table>

-8022643

-5531360

38670247

35084279

-0.21

-0.16

-8022643 -5531360

-164073

-243

-8186716

-5531603

38670247 35084279

97039

14329

38767286

35098608

-0.21

-0.16

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options and Warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,517,160</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,009,959</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Unvested Restricted Stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">302,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">304,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,819,660</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,314,459</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

6517160

7009959

302500

304500

6819660

7314459

3900000

XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Dec. 31, 2020	Feb. 05, 2021
Cover [Abstract]
Entity Registrant Name	CEL-SCI CORPORATION
Entity Central Index Key	0000725363
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2020
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		40,529,278
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-11889
Entity Incorporation State Country Code	CO
Entity Tax Identification Number	84-0916344
Entity Address Address Line 1	8229 Boone Boulevard
Entity Address Address Line 2	Suite 802
Entity Address City Or Town	Vienna
Entity Address State Or Province	VA
Entity Address Postal Zip Code	22182
City Area Code	703
Local Phone Number	506-9460
Security 12b Title	Common Stock
Trading Symbol	CVM
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes

XML 11 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Current Assets:
Cash and cash equivalents	$ 21,860,482	$ 15,508,909
Receivables	54,922	54,922
Prepaid expenses	629,894	1,313,432
Supplies used for R&D and manufacturing	1,152,837	820,052
Total current assets	23,698,135	17,697,315
Finance lease right of use assets	13,382,401	13,811,849
Operating lease right of use assets	1,160,305	1,198,958
Property and equipment, net	9,401,891	5,843,993
Patent costs, net	300,356	313,422
Deposits	1,670,917	1,670,917
Total Assets	49,614,005	40,536,454
Current Liabilities:
Accounts payable	3,092,856	2,023,067
Accrued expenses	616,163	510,515
Due to employees	458,740	448,022
Derivative instruments, current portion	2,040,773	213,787
Lease liabilities, current portion	1,125,337	1,070,123
Total current liabilities	7,333,869	4,265,514
Derivative instruments, net of current portion	750,154	3,551,826
Finance lease obligations, net of current portion	11,495,840	11,753,100
Operating lease obligations, net of current portion	1,073,470	1,114,340
Other liabilities	125,000	125,000
Total liabilities	20,778,333	20,809,780
Commitments and Contingencies	0	0
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding	0	0
Common stock, $.01 par value - 600,000,000 shares authorized; 39,767,058 and 38,730,150 shares issued and outstanding at December 31, 2020 and September 30, 2020, respectively	397,671	387,302
Additional paid-in capital	418,210,168	401,174,675
Accumulated deficit	(389,772,167)	(381,835,303)
Total stockholders' equity	28,835,672	19,726,674
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 49,614,005	$ 40,536,454

XML 12 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2020	Sep. 30, 2020
CONDENSED BALANCE SHEETS
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	200,000	200,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	39,767,058	38,730,150
Common stock, shares outstanding	39,767,058	38,730,150

XML 13 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)
Grant income	$ 0	$ 35,506
Operating Expenses:
Research and development	5,414,760	4,252,813
General and administrative	3,316,156	2,638,896
Total operating expenses	8,730,916	6,891,709
Operating loss	(8,730,916)	(6,856,203)
Other income	0	18,448
Gain on derivative instruments	932,836	766,509
Other non-operating gains	121,606	790,669
Interest expense, net	(260,390)	(250,783)
Net loss	(7,936,864)	(5,531,360)
Modification of warrants	(85,779)	0
Net loss available to common shareholders	$ (8,022,643)	$ (5,531,360)
Net loss per common share
BASIC	$ (0.21)	$ (0.16)
DILUTED	$ (0.21)	$ (0.16)
Weighted average common shares outstanding
BASIC	38,670,247	35,084,279
DILUTED	38,767,286	35,098,608

XML 14 R5.htm IDEA: XBRL DOCUMENT

STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Sep. 30, 2019		35,231,776
Balance, amount at Sep. 30, 2019	$ 5,133,667	$ 352,318	$ 358,507,603	$ (353,726,254)
Adoption of new accounting standard	2,146,195			2,146,195
Issuance of common stock, shares		606,395
Issuance of common stock, amount	5,050,003	$ 6,064	5,043,939	0
Warrant exercises, shares		132,900
Warrant exercises, amount	297,101	$ 1,329	295,772	0
Equity based compensation - employees, amount	1,800,225	$ 0	1,800,225	0
401(k) contributions paid in common stock, shares		4,474
401(k) contributions paid in common stock, amount	40,937	$ 45	40,892	0
Stock issued to nonemployees for service, shares		15,819
Stock issued to nonemployees for service, amount	84,447	$ 158	84,289	0
Purchase of stock by officer, shares		3,725
Purchase of stock by officer, amount	25,000	$ 37	24,963	0
Share issuance costs	(92,150)	0	(92,150)	0
Net loss	(5,531,360)	$ 0	0	(5,531,360)
Balance, shares at Dec. 31, 2019		35,995,089
Balance, amount at Dec. 31, 2019	8,954,065	$ 359,951	365,705,533	(357,111,419)
Balance, shares at Sep. 30, 2020		38,730,150
Balance, amount at Sep. 30, 2020	19,726,674	$ 387,302	401,174,675	(381,835,303)
Warrant exercises, shares		15,000
Warrant exercises, amount	89,250	$ 150	89,100	0
Equity based compensation - employees, amount	3,296,309	$ (20)	3,296,329	0
401(k) contributions paid in common stock, shares		3,564
401(k) contributions paid in common stock, amount	41,671	$ 36	41,635	0
Stock issued to nonemployees for service, shares		15,044
Stock issued to nonemployees for service, amount	152,450	$ 150	152,300	0
Share issuance costs	(117,021)	0	(117,021)	0
Net loss	(7,936,864)	$ 0	0	(7,936,864)
Proceeds from the sale of common stock, shares		1,000,000
Proceeds from the sale of common stock, amount	$ 13,559,500	$ 10,000	13,549,500	0
Equity based compensation - employees, shares		(2,000)
Option exercises, shares	5,300	5,300
Option exercises, amount	$ 23,511	$ 53	23,458	0
Modification of warrants	192	$ 0	192	0
Balance, shares at Dec. 31, 2020		39,767,058
Balance, amount at Dec. 31, 2020	$ 28,835,672	$ 397,671	$ 418,210,168	$ (389,772,167)

XML 15 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)
Net loss	$ (7,936,864)	$ (5,531,360)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	550,682	502,540
Share-based payments for services	248,660	155,740
Equity based compensation	3,296,309	1,800,225
Common stock contributed to 401(k) plan	41,671	40,937
Gain on derivative instruments	(932,836)	(766,509)
Modification of warrants	192	0
(Increase)/decrease in assets:
Receivables	532,328	(28,278)
Prepaid expenses	(332,785)	86,567
Supplies used for R&D and manufacturing	0	(123,512)
Increase/(decrease) in liabilities:
Accounts payable	532,679	(393,064)
Accrued expenses	143,028	80,432
Due to employees	10,718	76,520
Other liabilities	18,319	(1,914)
Net cash used in operating activities	(3,827,899)	(4,101,676)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(3,149,820)	(101,820)
Proceeds from the sale of equipment	0	4,500
Expenditures for patent costs	0	(12,390)
Net cash used in investing activities	(3,149,820)	(109,710)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	13,559,500	5,050,003
Payments of stock issuance costs	(79,499)	(31,080)
Proceeds from the purchase of stock by officer	0	25,000
Proceeds from exercises of warrants and options	70,911	297,101
Payments on obligations under finance lease	(221,620)	(191,034)
Net cash provided by financing activities	13,329,292	5,149,990
NET INCREASE IN CASH AND CASH EQUIVALENTS	6,351,573	938,604
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	15,508,909	8,444,774
CASH AND CASH EQUIVALENTS, END OF PERIOD	21,860,482	9,383,378
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment included in current liabilities	1,700,969	296,941
Capitalizable patent costs included in current liabilities	15,000	0
Finance lease obligation included in accounts payable	1,752	745
Prepaid consulting services paid with issuance of common stock	243,687	(71,293)
Exercise of derivative liabilities	41,850	0
Financing costs included in current liabilities	88,021	76,650
Cash paid for interest	$ 277,618	$ 295,107

XML 16 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Dec. 31, 2020

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A.	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Summary of Significant Accounting Policies:

Newly Adopted Accounting Pronouncements

New Accounting Pronouncements

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

XML 17 R8.htm IDEA: XBRL DOCUMENT

OPERATIONS AND FINANCING

3 Months Ended

Dec. 31, 2020

OPERATIONS AND FINANCING

B. OPERATIONS AND FINANCING

B.	OPERATIONS AND FINANCING

Impact of COVID-19 Pandemic

XML 18 R9.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY

3 Months Ended

Dec. 31, 2020

STOCKHOLDERS EQUITY

C. STOCKHOLDERS' EQUITY

C.	STOCKHOLDERS’ EQUITY

Proceeds from the Sale of Common Stock

Equity Compensation

Underlying share information for equity compensation plans as of December 31, 2020 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Options Plans		138,400		85,895		N/A		213
Non-Qualified Stock Option Plans		9,987,200		8,527,787		N/A		1,201,832
Stock Bonus Plans		783,760		N/A		348,660		435,067
Stock Compensation Plans		634,000		N/A		150,695		464,895
Incentive Stock Bonus Plan		640,000		N/A		614,500		25,500

Underlying share information for equity compensation plans as of September 30, 2020 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		138,400		85,895		N/A		213
Non-Qualified Stock Option Plans		9,987,200		8,567,808		N/A		1,167,166
Stock Bonus Plans		783,760		N/A		345,096		438,631
Stock Compensation Plans		634,000		N/A		150,695		464,895
Incentive Stock Bonus Plan		640,000		N/A		616,500		23,500

Stock option activity:

	Three Months Ended December 31,
	2020		2019
Options granted		7,500		1,000
Options exercised		5,300		-
Options forfeited		42,166		-
Options expired		55		36

Stock-Based Compensation Expense

	Three months Ended December 31,
	2020		2019
Employees	$	3,296,309	$	1,800,225
Non-employees	$	248,660	$	155,740

Warrants and Non-Employee Options

The following chart represents the warrants and non-employee options outstanding at December 31, 2020:

Warrant/Options	Issue Date	Shares Issuable upon Exercise of Warrants/ Options		Exercise Price		Expiration Date	Reference
Series N	8/18/2008		85,339	$	3.00	8/18/2021		2
Series UU	6/11/2018		93,603	$	2.80	6/30/2021		2
Series X	1/13/2016		120,000	$	9.25	7/13/2021		2
Series Y	2/15/2016		26,000	$	12.00	8/15/2021		2
Series ZZ	5/23/2016		20,000	$	13.75	5/18/2021	*
Series BB	8/26/2016		16,000	$	13.75	8/22/2021	*
Series Z	5/23/2016		264,000	$	13.75	11/23/2021	*
Series FF	12/8/2016		68,048	$	3.91	12/1/2021	*
Series CC	12/8/2016		143,643	$	5.00	12/8/2021		1
Series HH	2/23/2017		200	$	3.13	2/16/2022	*
Series AA	8/26/2016		200,000	$	13.75	2/22/2022	*
Series MM	6/22/2017		797,633	$	1.86	6/22/2022	*
Series NN	7/24/2017		348,842	$	2.52	7/24/2022	*
Series RR	10/30/2017		417,649	$	1.65	10/30/2022	*
Series SS	12/19/2017		326,064	$	2.09	12/18/2022	*
Series TT	2/5/2018		361,564	$	2.24	2/5/2023		2
Consultants	7/28/2017 - 11/18/2020		15,000	$	2.18-11.61	11/17/2022 - 7/27/2027		3

* No current period changes to these warrants

1.	Derivative Liabilities

The table below presents the fair value of the warrant liabilities at the balance sheet dates:

	December 31, 2020		September 30, 2020
Series W warrants	$	-	$	73,570
Series Z warrants		929,539		1,207,902
Series ZZ warrants		23,177		75,044
Series AA warrants		748,404		1,082,212
Series BB warrants		34,541		65,173
Series CC warrants		1,053,517		1,259,712
Series HH warrants		1,749		2,000
Total warrant liabilities	$	2,790,927	$	3,765,613

The table below presents the gains and (losses) on the warrant liabilities for the three months ended December 31:

	2020		2019
Series V warrants	$	-	$	555,031
Series W warrants		73,570		151,374
Series Z warrants		278,363		10,549
Series ZZ warrants		51,867		14,847
Series AA warrants		333,808		64,978
Series BB warrants		30,632		(431	)
Series CC warrants		164,345		(22,681	)
Series FF warrants		-		(7,189	)
Series HH warrants		251		(82	)
Series JJ warrants		-		(130	)
Series LL warrants		-		243
Net gain on warrant liabilities	$	932,836	$	766,509

Changes in Warrant Liabilities

On October 28, 2020, 688,930 Series W warrants, with an exercise price of $16.75 expired.

During the three months ended December 31, 2020, 5,000 Series CC warrants were exercised at an exercise price of $5.00 for gross proceeds of $25,000.

No warrants recorded as liabilities were exercised during the three months ended December 31, 2019.

2.	Equity Warrants

Changes in Equity Warrants

Exercise of Equity Warrants

During the three months ended December 31, 2020, 10,000 Series TT warrants were exercised at an exercise price of $2.24 for gross proceeds of $22,400.

The following warrants recorded as equity were exercised during the three months ended December 31, 2019.

Warrants	Warrants Exercised		Exercise Price		Proceeds
Series OO		10,000	$	2.52	$	25,200
Series SS		22,632	$	2.09		47,301
Series TT		100,628	$	2.24		224,600
		132,900			$	297,101

3.	Options and Shares Issued to Consultants

4.	Securities Purchase Agreement

As of December 31, 2020, Ergomed held 93,521 shares for resale.

XML 19 R10.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS

3 Months Ended

Dec. 31, 2020

FAIR VALUE MEASUREMENTS

D. FAIR VALUE MEASUREMENTS

D.	FAIR VALUE MEASUREMENTS

	·	Level 1 - Observable inputs such as quoted prices in active markets for identical assets or liabilities

	·	Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

	·	Level 3 - Unobservable inputs that reflect management’s assumptions

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2020:

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

2,790,927

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2020:

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

3,765,613

	3 months ended December 31, 2020			12 months ended September 30, 2020

Beginning balance	$	3,765,613		$	6,488,310
Issuances		-			-
Exercises		(41,850	)		(3,071,775	)
Realized and unrealized (gains) and losses		(932,836	)		349,078
Ending balance	$	2,790,927		$	3,765,613

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R11.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Dec. 31, 2020

RELATED PARTY TRANSACTIONS

E. RELATED PARTY TRANSACTIONS

E.	RELATED PARTY TRANSACTIONS

XML 21 R12.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Dec. 31, 2020

COMMITMENTS AND CONTINGENCIES

F. COMMITMENTS AND CONTINGENCIES

F.	COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

Lease Agreements

Approximate future minimum lease payments under finance leases as of December 31, 2020 are as follows:

Nine months ending September 30, 2021	$	1,469,000
Year ending September 30,
2022		2,014,000
2023		2,083,000
2024		2,148,000
2025		2,218,000
2026		2,294,000
Thereafter		5,028,000
Total future minimum lease obligation		17,254,000
Less imputed interest on finance lease obligations		(4,789,000	)
Net present value of lease finance lease obligations	$	12,465,000

As of December 31, 2020, future minimum lease payments on operating leases are as follows:

Nine months ending September 30, 2021	$	193,000
Year ending September 30,
2022		264,000
2022		272,000
2024		280,000
2025		288,000
2026		207,000
Thereafter		80,000
Total future minimum lease obligation		1,584,000
Less imputed interest on operating lease obligation		(354,000	)
Net present value of operating lease obligation	$	1,230,000

XML 22 R13.htm IDEA: XBRL DOCUMENT

PATENTS

3 Months Ended

Dec. 31, 2020

PATENTS

G. PATENTS

PATENTS

Nine months ending September 30, 2021	$	39,000
Year ending September 30,
2022		48,000
2023		38,000
2024		30,000
2025		27,000
2026		24,000
Thereafter		94,000
Total	$	300,000

XML 23 R14.htm IDEA: XBRL DOCUMENT

LOSS PER COMMON SHARE

3 Months Ended

Dec. 31, 2020

LOSS PER COMMON SHARE

H. LOSS PER COMMON SHARE

H.	LOSS PER COMMON SHARE

The following tables provide the details of the basic and diluted loss per-share computations:

	Three months ended December 31,
	2020			2019
Loss per share - basic
Net loss available to common shareholders - basic	$	(8,022,643	)	$	(5,531,360	)
Weighted average shares outstanding - basic		38,670,247			35,084,279
Basic loss per common share	$	(0.21	)	$	(0.16	)

Loss per share - diluted
Net loss available to common shareholders - basic	$	(8,022,643	)	$	(5,531,360	)
Gain on derivatives (1)		(164,073	)		(243	)
Net loss available to common shareholders - diluted	$	(8,186,716	)	$	(5,531,603	)

Weighted average shares outstanding - basic		38,670,247			35,084,279
Incremental shares underlying dilutive - warrants and options (1)		97,039			14,329
Weighted average shares outstanding - diluted		38,767,286			35,098,608
Diluted loss earnings per common share	$	(0.21	)	$	(0.16	)

(1) Includes Series CC and HH warrants for the three months ended December 31, 2020 and Series LL warrants for the three months ended December 31, 2019.

	2020		2019

Options and Warrants		6,517,160		7,009,959
Unvested Restricted Stock		302,500		304,500
Total		6,819,660		7,314,459

XML 24 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Dec. 31, 2020

SUBSEQUENT EVENTS

J. SUBSEQUENT EVENTS

J.	SUBSEQUENT EVENTS

Between January 1, 2021 and February 5, 2021, the Company received approximately $3.9 million through the exercise of options and warrants to purchase shares of the Company’s common stock.

XML 25 R16.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)	3 Months Ended
	Dec. 31, 2020
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Property Equipment	Property and Equipment - Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.
Patents	Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.
Research and Development Costs	Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the facts that give rise to the revision become known.
Leases	Leases - The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment, over a period of time, in exchange for consideration, as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. For purposes of calculating lease liabilities, lease and non-lease components are combined.
Income Taxes	Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2020 and September 30, 2020.
Derivative Instruments	Derivative Instruments - The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim reporting period.
Stock-Based Compensation	Stock-Based Compensation - Compensation cost for stock-based awards to employees and non-employees is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation - Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as expense over the requisite service or vesting period. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s common stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Vesting of restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.
New Accounting Pronouncements	Newly Adopted Accounting Pronouncements In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement - Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820).” Under the new standard, the amount and reason for a transfer between Level 1 and Level 2 of the fair value hierarchy is no longer required to be disclosed, but public companies are required to disclose a range and weighted average of significant unobservable inputs for Level 3 fair value measurements. The Company adopted the new standard on July 1, 2020 with no impact to the Company’s financial statements. New Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40 and are effective for the Company for the fiscal year ending September 30, 2025, including interim periods within that fiscal year. Early adoption is permitted. All of the Company’s liability classified warrants will be expired by that date and the Company does not expect the adoption to have a significant impact on its financial statements. The effect, if any, will largely depend on the composition and terms of the financial instruments at the time of adoption. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. This standard will be effective for the Company on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on the financial statements. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327

+ Details

XML 26 R17.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Tables)

3 Months Ended

Dec. 31, 2020

STOCKHOLDERS EQUITY

Stock options, stock bonuses and compensation granted by the Company

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Options Plans		138,400		85,895		N/A		213
Non-Qualified Stock Option Plans		9,987,200		8,527,787		N/A		1,201,832
Stock Bonus Plans		783,760		N/A		348,660		435,067
Stock Compensation Plans		634,000		N/A		150,695		464,895
Incentive Stock Bonus Plan		640,000		N/A		614,500		25,500

Underlying share information for equity compensation plans as of September 30, 2020 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		138,400		85,895		N/A		213
Non-Qualified Stock Option Plans		9,987,200		8,567,808		N/A		1,167,166
Stock Bonus Plans		783,760		N/A		345,096		438,631
Stock Compensation Plans		634,000		N/A		150,695		464,895
Incentive Stock Bonus Plan		640,000		N/A		616,500		23,500

Stock option activity

	Three Months Ended December 31,
	2020		2019
Options granted		7,500		1,000
Options exercised		5,300		-
Options forfeited		42,166		-
Options expired		55		36

Stock-based compensation expense

	Three months Ended December 31,
	2020		2019
Employees	$	3,296,309	$	1,800,225
Non-employees	$	248,660	$	155,740

Derivative liabilities, warrants and other options

Warrant/Options	Issue Date	Shares Issuable upon Exercise of Warrants/ Options		Exercise Price		Expiration Date	Reference
Series N	8/18/2008		85,339	$	3.00	8/18/2021		2
Series UU	6/11/2018		93,603	$	2.80	6/30/2021		2
Series X	1/13/2016		120,000	$	9.25	7/13/2021		2
Series Y	2/15/2016		26,000	$	12.00	8/15/2021		2
Series ZZ	5/23/2016		20,000	$	13.75	5/18/2021	*
Series BB	8/26/2016		16,000	$	13.75	8/22/2021	*
Series Z	5/23/2016		264,000	$	13.75	11/23/2021	*
Series FF	12/8/2016		68,048	$	3.91	12/1/2021	*
Series CC	12/8/2016		143,643	$	5.00	12/8/2021		1
Series HH	2/23/2017		200	$	3.13	2/16/2022	*
Series AA	8/26/2016		200,000	$	13.75	2/22/2022	*
Series MM	6/22/2017		797,633	$	1.86	6/22/2022	*
Series NN	7/24/2017		348,842	$	2.52	7/24/2022	*
Series RR	10/30/2017		417,649	$	1.65	10/30/2022	*
Series SS	12/19/2017		326,064	$	2.09	12/18/2022	*
Series TT	2/5/2018		361,564	$	2.24	2/5/2023		2
Consultants	7/28/2017 - 11/18/2020		15,000	$	2.18-11.61	11/17/2022 - 7/27/2027		3

Tabular disclosure of derivative liabilities at fair value

	December 31, 2020		September 30, 2020
Series W warrants	$	-	$	73,570
Series Z warrants		929,539		1,207,902
Series ZZ warrants		23,177		75,044
Series AA warrants		748,404		1,082,212
Series BB warrants		34,541		65,173
Series CC warrants		1,053,517		1,259,712
Series HH warrants		1,749		2,000
Total warrant liabilities	$	2,790,927	$	3,765,613

Schedule of gains and (losses) on derivative liabilities

	2020		2019
Series V warrants	$	-	$	555,031
Series W warrants		73,570		151,374
Series Z warrants		278,363		10,549
Series ZZ warrants		51,867		14,847
Series AA warrants		333,808		64,978
Series BB warrants		30,632		(431	)
Series CC warrants		164,345		(22,681	)
Series FF warrants		-		(7,189	)
Series HH warrants		251		(82	)
Series JJ warrants		-		(130	)
Series LL warrants		-		243
Net gain on warrant liabilities	$	932,836	$	766,509

Warrants recorded as equity exercised

Warrants	Warrants Exercised		Exercise Price		Proceeds
Series OO		10,000	$	2.52	$	25,200
Series SS		22,632	$	2.09		47,301
Series TT		100,628	$	2.24		224,600
		132,900			$	297,101

- Definition

Tabular disclosure of an equity-based arrangement (such as stock or unit options and stock or unit awards) with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.

+ References + Details

XML 27 R18.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Dec. 31, 2020

FAIR VALUE MEASUREMENTS

Measured at fair value on a recurring basis

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

2,790,927

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

3,765,613

Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)

	3 months ended December 31, 2020			12 months ended September 30, 2020

Beginning balance	$	3,765,613		$	6,488,310
Issuances		-			-
Exercises		(41,850	)		(3,071,775	)
Realized and unrealized (gains) and losses		(932,836	)		349,078
Ending balance	$	2,790,927		$	3,765,613

XML 28 R19.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Dec. 31, 2020

COMMITMENTS AND CONTINGENCIES

Schedule of future minimum payments under finance leases

Nine months ending September 30, 2021	$	1,469,000
Year ending September 30,
2022		2,014,000
2023		2,083,000
2024		2,148,000
2025		2,218,000
2026		2,294,000
Thereafter		5,028,000
Total future minimum lease obligation		17,254,000
Less imputed interest on finance lease obligations		(4,789,000	)
Net present value of lease finance lease obligations	$	12,465,000

Nine months ending September 30, 2021	$	193,000
Year ending September 30,
2022		264,000
2022		272,000
2024		280,000
2025		288,000
2026		207,000
Thereafter		80,000
Total future minimum lease obligation		1,584,000
Less imputed interest on operating lease obligation		(354,000	)
Net present value of operating lease obligation	$	1,230,000

XML 29 R20.htm IDEA: XBRL DOCUMENT

PATENTS (Tables)

3 Months Ended

Dec. 31, 2020

PATENTS

Schedule of total estimated future amortization

Nine months ending September 30, 2021	$	39,000
Year ending September 30,
2022		48,000
2023		38,000
2024		30,000
2025		27,000
2026		24,000
Thereafter		94,000
Total	$	300,000

XML 30 R21.htm IDEA: XBRL DOCUMENT

LOSS PER COMMON SHARE (Tables)

3 Months Ended

Dec. 31, 2020

LOSS PER COMMON SHARE

Schedule of basic and diluted loss per-share computations

	Three months ended December 31,
	2020			2019
Loss per share - basic
Net loss available to common shareholders - basic	$	(8,022,643	)	$	(5,531,360	)
Weighted average shares outstanding - basic		38,670,247			35,084,279
Basic loss per common share	$	(0.21	)	$	(0.16	)

Loss per share - diluted
Net loss available to common shareholders - basic	$	(8,022,643	)	$	(5,531,360	)
Gain on derivatives (1)		(164,073	)		(243	)
Net loss available to common shareholders - diluted	$	(8,186,716	)	$	(5,531,603	)

Weighted average shares outstanding - basic		38,670,247			35,084,279
Incremental shares underlying dilutive - warrants and options (1)		97,039			14,329
Weighted average shares outstanding - diluted		38,767,286			35,098,608
Diluted loss earnings per common share	$	(0.21	)	$	(0.16	)

Schedule of antidilutive securities

	2020		2019

Options and Warrants		6,517,160		7,009,959
Unvested Restricted Stock		302,500		304,500
Total		6,819,660		7,314,459

XML 31 R22.htm IDEA: XBRL DOCUMENT

A BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended
	Dec. 31, 2020
Patents [Member]
Patent useful life	17 years

XML 32 R23.htm IDEA: XBRL DOCUMENT

C STOCKHOLDERS EQUITY (Details) - shares	Dec. 31, 2020	Sep. 30, 2020
Incentive Stock Option Plans [Member]
Shares reserved for outstanding options	85,895	85,895
Remaining options/shares under plans	213	213
Total shares reserved under plans	138,400	138,400
Non-Qualified Stock Option Plans [Member]
Shares reserved for outstanding options	8,527,787	8,567,808
Remaining options/shares under plans	1,201,832	1,167,166
Total shares reserved under plans	9,987,200	9,987,200
Stock Bonus Plans [Member]
Remaining options/shares under plans	435,067	438,631
Total shares reserved under plans	783,760	783,760
Shares issued	348,660	345,096
Stock Compensation Plan [Member]
Remaining options/shares under plans	464,895	464,895
Total shares reserved under plans	634,000	634,000
Shares issued	150,695	150,695
Incentive Stock Bonus Plan [Member]
Remaining options/shares under plans	25,500	23,500
Total shares reserved under plans	640,000	640,000
Shares issued	614,500	616,500

XML 33 R24.htm IDEA: XBRL DOCUMENT

C STOCKHOLDERS EQUITY (Details 1) - shares	3 Months Ended
C STOCKHOLDERS EQUITY (Details 1) - shares	Dec. 31, 2020	Dec. 31, 2019
STOCKHOLDERS EQUITY
Options granted	7,500	1,000
Options exercised	5,300
Options forfeited	42,166
Options expired	55	36

XML 34 R25.htm IDEA: XBRL DOCUMENT

C STOCKHOLDERS EQUITY (Details 2) - USD ($)	3 Months Ended
C STOCKHOLDERS EQUITY (Details 2) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
STOCKHOLDERS EQUITY
Employees stock based compensation expense	$ 3,296,309	$ 1,800,225
Non- Employees stock based compensation expense	$ 248,660	$ 155,740

XML 35 R26.htm IDEA: XBRL DOCUMENT

C STOCKHOLDERS EQUITY (Details 3)	3 Months Ended
C STOCKHOLDERS EQUITY (Details 3)	Dec. 31, 2020 $ / shares shares
Series N [Member]
Shares issuable upon exercise of warrant/options \| shares	85,339
Exercise price	$ 3.00
Issue date	8/18/2008
Expiration date	8/18/2021
Series UU [Member]
Shares issuable upon exercise of warrant/options \| shares	93,603
Exercise price	$ 2.80
Issue date	6/11/2018
Expiration date	6/30/2021
Series X [Member]
Shares issuable upon exercise of warrant/options \| shares	120,000
Exercise price	$ 9.25
Issue date	1/13/2016
Expiration date	7/13/2021
Series Y [Member]
Shares issuable upon exercise of warrant/options \| shares	26,000
Exercise price	$ 12.00
Issue date	2/15/2016
Expiration date	8/15/2021
Series ZZ [Member]
Shares issuable upon exercise of warrant/options \| shares	20,000
Exercise price	$ 13.75
Issue date	5/23/2016
Expiration date	5/18/2021
Series BB [Member]
Shares issuable upon exercise of warrant/options \| shares	16,000
Exercise price	$ 13.75
Issue date	8/26/2016
Expiration date	8/22/2021
Series Z [Member]
Shares issuable upon exercise of warrant/options \| shares	264,000
Exercise price	$ 13.75
Issue date	5/23/2016
Expiration date	11/23/2021
Series FF [Member]
Shares issuable upon exercise of warrant/options \| shares	68,048
Exercise price	$ 3.91
Issue date	12/8/2016
Expiration date	12/1/2021
Series CC [Member]
Shares issuable upon exercise of warrant/options \| shares	143,643
Exercise price	$ 5.00
Issue date	12/8/2016
Expiration date	12/8/2021
Series HH [Member]
Shares issuable upon exercise of warrant/options \| shares	200
Exercise price	$ 3.13
Issue date	2/23/2017
Expiration date	2/16/2022
Series AA [Member]
Shares issuable upon exercise of warrant/options \| shares	200,000
Exercise price	$ 13.75
Issue date	8/26/2016
Expiration date	2/22/2022
Series MM [Member]
Shares issuable upon exercise of warrant/options \| shares	797,633
Exercise price	$ 1.86
Issue date	6/22/2017
Expiration date	6/22/2022
Series NN [Member]
Shares issuable upon exercise of warrant/options \| shares	348,842
Exercise price	$ 2.52
Issue date	7/24/2017
Expiration date	7/24/2022
Series RR [Member]
Shares issuable upon exercise of warrant/options \| shares	417,649
Exercise price	$ 1.65
Issue date	10/30/2017
Expiration date	10/30/2022
Series SS [Member]
Shares issuable upon exercise of warrant/options \| shares	326,064
Exercise price	$ 2.09
Issue date	12/19/2017
Expiration date	12/18/2022
Series TT [Member]
Shares issuable upon exercise of warrant/options \| shares	361,564
Exercise price	$ 2.24
Issue date	2/5/2018
Expiration date	2/5/2023
Consultants [Member]
Shares issuable upon exercise of warrant/options \| shares	15,000
Expiration date	November 17, 2022
Consultants [Member] \| Minimum [Member]
Exercise price	$ 2.18
Issue date	7/28/2017
Expiration date	11/17/2022
Consultants [Member] \| Maximum [Member]
Exercise price	$ 11.61
Issue date	11/18/2020
Expiration date	7/27/2027

XML 36 R27.htm IDEA: XBRL DOCUMENT

C STOCKHOLDERS EQUITY (Details 4) - USD ($)	3 Months Ended
C STOCKHOLDERS EQUITY (Details 4) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2019
STOCKHOLDERS EQUITY
Series W warrants	$ 0		$ 73,570
Series Z warrants	929,539		1,207,902
Series ZZ warrants	23,177		75,044
Series AA warrants	748,404		1,082,212
Series BB warrants	34,541		65,173
Series CC warrants	1,053,517		1,259,712
Series HH warrants	1,749		2,000
Total warrant liabilities	2,790,927		$ 3,765,613
Gains (losses) on Series V warrants	0	$ 555,031
Gains (losses) on Series W warrants	73,570	151,374
Gains (losses) on Series Z warrants	278,363	10,549
Gains (losses) on Series ZZ warrants	51,867	14,847
Gains (losses) on Series AA warrants	333,808	64,978
Gains (losses) on Series BB warrants	30,632	(431)
Gains (losses) on Series CC warrants	164,345	(22,681)
Gains (losses) on Series FF warrants	0	(7,189)
Gains (losses) on Series HH warrants	251	(82)
Gains (losses) on Series JJ warrants	0	(130)
Gains (losses) on Series LL warrants	0	243
Net loss on warrant liabilities	$ 932,836	$ 766,509

XML 37 R28.htm IDEA: XBRL DOCUMENT

C STOCKHOLDERS EQUITY (Details 5)	3 Months Ended
C STOCKHOLDERS EQUITY (Details 5)	Dec. 31, 2019 USD ($) $ / shares shares
Warrants exercised \| shares	132,900
Proceeds \| $	$ 297,101
Series SS [Member]
Warrants exercised \| shares	22,632
Proceeds \| $	$ 47,301
Exercise price \| $ / shares	$ 2.09
Series TT [Member]
Warrants exercised \| shares	100,628
Proceeds \| $	$ 224,600
Exercise price \| $ / shares	$ 2.24
Series OO [Member]
Warrants exercised \| shares	10,000
Proceeds \| $	$ 25,200
Exercise price \| $ / shares	$ 2.52

XML 38 R29.htm IDEA: XBRL DOCUMENT

C STOCKHOLDERS EQUITY (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
C STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	Dec. 07, 2020	Sep. 30, 2020	Jun. 25, 2020	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2019
Prepaid expenses				$ 244,000		$ 395,000
Proceeds from the sale of common stock				1,000,000
Public offering price per share				$ 14.65
Proceeds from public offering				$ 13,600,000
Additional shares of common stock				150,000
Fair value of stock option				$ 28,000
Weighted average grant date fair value				$ 5.65
Proceeds from warrants exercised				$ 70,911	$ 297,101
Stock options granted				7,500	1,000
Warrants expired				55	36
Common stock shares issued		38,730,150		39,767,058
Common stock valued		$ 387,302		$ 397,671
Consulting Agreements [Member]
Total expense				$ 249,000	$ 156,000
Series W Warrants [Member]
Common stock price per share			$ 16.75
Warrants expired			688,930
Non-Qualified Stock Option Plans [Member]
Stock options granted				10,000
Series X [Member]
Incremental cost				$ 85,000
Expiration date description	the expiration date of the Series X warrants was extended six months from January 13, 2021 to July 13, 2021
Expiration date				7/13/2021
Series Y [Member]
Incremental cost	$ 41,000
Expiration date				8/15/2021
Series CC [Member]
Warrants exercised				5,000
Warrant exercise price				$ 5.00
Proceeds from warrants exercised				$ 25,000
Expiration date				12/8/2021
Series TT [Member]
Warrants exercised				10,000
Warrant exercise price				$ 2.24
Proceeds from warrants exercised				$ 22,400
Expiration date				2/5/2023
Series UU warrants [Member]
Incremental cost				$ 192
Expiration date description	the expiration date of Series UU warrants were extended six months from December 31, 2020 to June 30, 2021
Series N Warrants [Member]
Incremental cost				$ 1,000
Expiration date description	the expiration date of the Series N warrants was extended six months from February 18, 2021 to August 18, 2021
Consultants One [Member]
Options issued		10,000		15,000
Ergomed [Member]
Common stock shares held				93,521
Common stock shares issued				9,000	98,350
Ergomed [Member] \| SPA [Member]
Common stock valued				$ 100,000	$ 800,000
Consultants [Member]
Exercise price				$ 11.61
Options issued				5,000
Expiration date				November 17, 2022
Consultants [Member] \| Restricted Stock [Member]
Weighted average grant date fair value				$ 12.45	$ 7.18
Common stock issued for service, shares				15,044	15,819

XML 39 R30.htm IDEA: XBRL DOCUMENT

D FAIR VALUE MEASUREMENTS (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Derivative instruments	$ 2,790,927	$ 3,765,613
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)
Derivative instruments	0	0
Significant Unobservable Inputs (Level 3)
Derivative instruments	2,790,927	3,765,613
Significant Other Observable Inputs (Level 2)
Derivative instruments	$ 0	$ 0

XML 40 R31.htm IDEA: XBRL DOCUMENT

D FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	3 Months Ended	12 Months Ended
D FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	Dec. 31, 2020	Sep. 30, 2019
FAIR VALUE MEASUREMENTS
Beginning balance	$ 3,765,613	$ 6,488,310
Issuances	0	0
Exercises	41,850	3,071,775
Realized and unrealized (gains) and losses	(932,836)	349,078
Ending balance	$ 2,790,927	$ 3,765,613

XML 41 R32.htm IDEA: XBRL DOCUMENT

ERELATED PARTY TRANSACTIONS (Details Narrative )	3 Months Ended
ERELATED PARTY TRANSACTIONS (Details Narrative )	Dec. 31, 2020 USD ($)
Deemed dividend	$ 86,000
Series UU warrants [Member]
Expiration date description	the expiration date of 93,603 Series UU warrants was extended from December 31, 2020 to June 30, 2021
Interest expense	$ 192

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

XML 42 R33.htm IDEA: XBRL DOCUMENT

F COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2020 USD ($)
COMMITMENTS AND CONTINGENCIES
Nine months ending September 30, 2021	$ 1,469,000
2022	2,014,000
2023	2,083,000
2024	2,148,000
2025	2,218,000
2026	2,294,000
Thereafter	5,028,000
Total future minimum lease obligation	17,254,000
Less imputed interest on finance lease obligations	(4,789,000)
Net present value of lease finance lease obligations	$ 12,465,000

XML 43 R34.htm IDEA: XBRL DOCUMENT

F COMMITMENTS AND CONTINGENCIES (Details 1)	Dec. 31, 2020 USD ($)
COMMITMENTS AND CONTINGENCIES
Nine months ending September 30, 2021	$ 193,000
2022	264,000
2023	272,000
2024	280,000
2025	288,000
2026	207,000
Thereafter	80,000
Total future minimum lease obligation	1,584,000
Less imputed interest on operating lease obligation	354,000
Net present value of operating lease obligation	$ 1,230,000

XML 44 R35.htm IDEA: XBRL DOCUMENT

F COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2019
Lease description		The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028
Non current assets		$ 1,700,000		$ 1,700,000
Clinical service trial		12,000,000
Cash paid related to finance leases		500,000	$ 500,000
Cash paid related to finance leases interest		300,000	300,000
Cash paid related to operating leases		$ 48,000	66,000
Weighted average discount rate		8.80%
Maturity years		7 years 9 months 18 days
Finance lease right of use assets		$ 13,400,000		13,800,000
Operating lease - liability		1,200,000		1,300,000
Operating lease liabilities current		200,000		100,000
Net book value operating lease right of use assets		1,200,000		1,200,000
Operating lease expense		66,000	68,000
Finance lease liability		12,500,000		12,700,000
Research and development expenses		34,000,000.0
Sublease rental income			18,000
Finance lease obligations, net of current portion		1,000,000.0		$ 900,000
Lease Agreement [Member]
Estimated cost	$ 10,500,000
Cost to improve the maufacturing facility	6,700,000
Increased lease payments	2,400,000
Ergomed [Member]
Research and development expenses		600,000	$ 900,000
Net of discount		$ 11,300,000
Landlord [Member]
Facility improvement costs	2,400,000
Cost incurred, initial	$ 8,100,000

XML 45 R36.htm IDEA: XBRL DOCUMENT

G PATENTS (Details)	Dec. 31, 2020 USD ($)
PATENTS
Nine months ending September 30, 2021	$ 39,000
2022	48,000
2023	38,000
2024	30,000
2025	27,000
2026	24,000
Thereafter	94,000
Total	$ 300,000

XML 46 R37.htm IDEA: XBRL DOCUMENT

G PATENTS (Details Narrative) - USD ($)	3 Months Ended
G PATENTS (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
PATENTS
Amortization of patent costs	$ 13,000	$ 13,000

XML 47 R38.htm IDEA: XBRL DOCUMENT

H LOSS PER COMMON SHARE (Details) - USD ($)	3 Months Ended
H LOSS PER COMMON SHARE (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Loss per share - basic
Net loss available to common shareholders - basic	$ (8,022,643)	$ (5,531,360)
Weighted average shares outstanding - basic	38,670,247	35,084,279
Basic loss per common share	$ (0.21)	$ (0.16)
Loss per share - diluted
Net loss available to common shareholders - basic	$ (8,022,643)	$ (5,531,360)
Gain on derivatives (1)	(164,073)	(243)
Net loss available to common shareholders - diluted	(8,186,716)	(5,531,603)
Weighted average shares outstanding - basic	$ 38,670,247	$ 35,084,279
Incremental shares underlying dilutive "in the money" warrants	97,039	14,329
Weighted average shares outstanding - diluted	38,767,286	35,098,608
Diluted loss earnings per common share	$ (0.21)	$ (0.16)

XML 48 R39.htm IDEA: XBRL DOCUMENT

H LOSS PER COMMON SHARE (Details 1) - shares	3 Months Ended
H LOSS PER COMMON SHARE (Details 1) - shares	Dec. 31, 2020	Dec. 31, 2019
Antidilutive securities	6,819,660	7,314,459
Options and Warrants
Antidilutive securities	6,517,160	7,009,959
Unvested Restricted Stock
Antidilutive securities	302,500	304,500

XML 49 R40.htm IDEA: XBRL DOCUMENT

J SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
J SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Feb. 05, 2021	Dec. 31, 2020	Dec. 31, 2019
Proceeds from exercise of options and warrants		$ 70,911	$ 297,101
Subsequent Event [Member]
Proceeds from exercise of options and warrants	$ 3,900,000

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
-8?20$3;8T.P6BP^0"X99K>]9!:GKU[O1,GK5VHO*GMEJW3)C3W57WKU7@N^J7=" MF++H!?W^L%=R67GO+@_W6NJ>>Z*,6!NI*MO8--Q(\5 _7F].R;VLY:TLI/D^ M\MK?A?!(*2M9RA]B,_+Z'JEWZF&FM/RA*L,+MM:J*$:>WUVX$=K(]9-FUD#F M_+9N6PR_S;@%&7G#OKWA5NK:M/]H[\\MX[VP?^[.[HR:RL((/>%&7&MUMY?5 ME^8V]BUZSFNT<3@Z+\)H]INY5I,U/JN%)7IXJA%T0!6]4[N:X]4O!0C M;ZSNA6[>QSX@WG3O9BR4$RE](>T%'6]:/$24-)G0A-$)N8KF43*FA,THS9E# M%P!TP?^A(V=+KD7E0(8 9/BO(%D>Y71!$PN83DFZI%F4QP[D ( H[$\ M'7^8I?,)S=@+0C^N',AS /+\_T1R'+$9FWB M-"%18J%7BT7D0+X&(%_C0OX:>VG"6K)IG-CLB9-KA^X-0/<&>S ^#K]F],7Y M)P?L+0#V%A=L&L49N8GF*TH6-&*KK!N#;JGN0[6ZCXN7T;E-BPE91EG^B>19 ME+!HW/:R2PC:!%TGBT6<=XG;##R;T;D==M0./GH$"4G%1[;*T@;QCUZ%].$C M^V.>,D9LOI(F>+:4L%F441<.TH:/[8W5%;,9:N-%Z,V?48-4X2.[ BS#GP,7 M$Y*%CVR+$Z6.G-DI:2'JERXCY H?61;/5+T#IXL)2<-'M@986\B9BPDIQ$=V MR*_J ;(\3I:9DY200 )D@40$3&P7$UR78"],R,G$G@C#97$<34@M M ?;2!,0D+B8DF0!9,B#F42T/(.4$V,L3$#-T,2'E!,C*@3$'+B9DG0#9.C#F MN8L)62? M@Z(.70Q(>L$R-:Q:[SG+-Z@NCLED(1"9 F!F$>9'D(6"I$M1)]? M:36@+B9DH1#90E/RM^NM$-P?0[80B'G0\A"X7(%KHFOV>8 M)Z8;(62>$-D\3]%(PK7FS3;\$23DG1#9.S/RS$RX0W8Q(>^$R-X!,8^3!O). MB.R=]^3)#H';^>[F-^2=0>N=WN'3RT9L924VB7U$;=O7O%@O-6D.W>;1X+Q9 MXFWOBF)LV])JKOCF\"7G\!7JW4]02P,$% @ !X),4CQA]1J- 0 3Q@ M !H !X;"]?S<3OQ D1;,8(0NB>CMQ^C"_W,+&9C^EN1;D+QKAX(S+]\7<9#>PK5 MH0O9N:E/89%7,78?SH5-Y9LR#-K.GZYG=FW?E/&Z[/>N*S?'/)01Z M&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z%ZAW\4Z]0[S4/CQZ[FN\ M_SNICM=K_>/VM^5]$Y\7Q0UG!_\/EK]02P,$% @ !X),4IC$(26B 0 MIA@ !, !;0V]N=&5N=%]4>7!E&ULS9G-;H,P$(1?!7&-@F,[37^4 MY-+VVN;0%W!A"2B +=M)D[>O(3]2JQ0U2J7.!0N\.S-XI>\ T[>=(1=MZZIQ ML[CPWCPPYM*":N42;:@).[FVM?+AUBZ94>E*+8F)T6C"4MUX:OS0MQKQ?/I$ MN5I7/GK>AL>NU,TLME2Y.'K<%[9>LU@94Y6I\F&?;9KLF\OPX)"$SJ[&%:5Q M@U 0L[,.[<[/!H>^UPU96V84+93U+ZH.56Q;,>=W%;FD7^),1IWG94J93M=U M:$FO57W\Y;]>D5F5S]&?=[XGY)U!+ 0(4 M Q0 ( >"3%('04UB@0 +$ 0 " 0 !D;V-0 M&UL4$L! A0#% @ !X),4H[3L7OM *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ !X), M4IE&PO=V]R:W-H965T&UL4$L! A0#% @ !X), M4MQ*ZM^)!@ &1D !@ ("!:PT 'AL+W=O"3%+P*SUIJ0( "H) 8 M " @2H4 !X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! A0#% @ !X),4OF&9:,W!P ER( !@ M ("!PAL 'AL+W=O"3%+^N.*'&P@ !<@ 8 " @2\C !X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L! A0#% @ !X),4M./(P5M" 1A0 !@ ("!]30 M 'AL+W=O"3%(F0QL8 M[PX / L 8 " @9@] !X;"]W;W)K&PO=V]R:W-H965T" M3%*1?IRC.@, &X' 9 " @<]2 !X;"]W;W)K&UL4$L! A0#% @ !X),4C; GVQ-"@ @AT !D M ("!0%8 'AL+W=O&PO=V]R M:W-H965T"3%)_0! P, 0 !0* M 9 " @:!C !X;"]W;W)K&UL M4$L! A0#% @ !X),4INS%)9+ @ #@4 !D ("!!V@ M 'AL+W=OZC- M/5(' "H$P &0 @(&):@ >&PO=V]R:W-H965T"3%+$3)!Y00< '04 9 M " @1)R !X;"]W;W)K&UL4$L! A0#% @ M!X),4HJNI^9- P 3@@ !D ("!BGD 'AL+W=O&PO=V]R:W-H965T"3%*(K/>>20( ,% 9 " @3F !X;"]W M;W)K&UL4$L! A0#% @ !X),4D'X$")\ P MH @ !D ("!N8( 'AL+W=O&PO=V]R:W-H965T"3%(I MF -?LP, ,,/ 9 " @&UL4$L! A0#% @ !X),4G842I-@ @ > 8 !D M ("!LHP 'AL+W=OE!>!5H" #/!0 &0 @(%)CP >&PO=V]R:W-H M965T"3%([,T(7\@8 !@R 9 M " @=J1 !X;"]W;W)K&UL4$L! M A0#% @ !X),4H^AE/%1! 7!( !D ("! YD 'AL M+W=O&PO=V]R:W-H965T"3%*+K1MG)P< %,C 9 " M@;6@ !X;"]W;W)K&UL4$L! A0#% @ !X), M4K.;IP:4 @ 4@< !D ("!$Z@ 'AL+W=OJ@ >&PO=V]R:W-H965T"3%)OR$%$?0( ,(% 9 " @="M !X;"]W;W)K M&UL4$L! A0#% @ !X),4AS.K3/. @ 5@@ M !D ("!A+ 'AL+W=O&PO=V]R:W-H965T"3%+A@^-4 MH@4 .\5 9 " @82V !X;"]W;W)K&UL4$L! A0#% @ !X),4D!N589+ @ M@8 !D M ("!7;P 'AL+W=O&PO=V]R:W-H965T M"3%(>;U).E@, "X, 9 M " @3;! !X;"]W;W)K&UL4$L! A0# M% @ !X),4L!B,L9Z @ K 8 !D ("! \4 'AL+W=O M&PO=V]R:W-H965T"3%)SK46T)@( -D( - " 6#* M !X;"]S='EL97,N>&UL4$L! A0#% @ !X),4I>*NQS $P( L M ( !L
"3%(\8?4:C0$ $\8 : " 6_1 !X M;"]?"3%*8Q"$E MH@$ *88 3 " 333 !;0V]N=&5N=%]4>7!E&UL 64$L%!@ P # !PT ?5 $! end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 113 350 1 false 45 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://cvm.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED BALANCE SHEETS Sheet http://cvm.com/role/CondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://cvm.com/role/CondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://cvm.com/role/CondensedStatementsOfOperationsUnaudited CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://cvm.com/role/StatementsOfStockholdersEquityUnaudited STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Statements 5 false false R6.htm 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 000008 - Disclosure - OPERATIONS AND FINANCING Sheet http://cvm.com/role/OperationsAndFinancing OPERATIONS AND FINANCING Notes 8 false false R9.htm 000009 - Disclosure - STOCKHOLDERS EQUITY Sheet http://cvm.com/role/StockholdersEquity STOCKHOLDERS EQUITY Notes 9 false false R10.htm 000010 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://cvm.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 10 false false R11.htm 000011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://cvm.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 11 false false R12.htm 000012 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://cvm.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 000013 - Disclosure - PATENTS Sheet http://cvm.com/role/PATENTS PATENTS Notes 13 false false R14.htm 000014 - Disclosure - LOSS PER COMMON SHARE Sheet http://cvm.com/role/LossPerCommonShare LOSS PER COMMON SHARE Notes 14 false false R15.htm 000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://cvm.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 000016 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) Sheet http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) Notes 16 false false R17.htm 000017 - Disclosure - STOCKHOLDERS EQUITY (Tables) Sheet http://cvm.com/role/StockholdersEquityTables STOCKHOLDERS EQUITY (Tables) Tables http://cvm.com/role/StockholdersEquity 17 false false R18.htm 000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://cvm.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://cvm.com/role/FairValueMeasurements 18 false false R19.htm 000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://cvm.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://cvm.com/role/CommitmentsAndContingencies 19 false false R20.htm 000020 - Disclosure - PATENTS (Tables) Sheet http://cvm.com/role/PatentsTables PATENTS (Tables) Tables http://cvm.com/role/PATENTS 20 false false R21.htm 000021 - Disclosure - LOSS PER COMMON SHARE (Tables) Sheet http://cvm.com/role/LossPerCommonShareTables LOSS PER COMMON SHARE (Tables) Tables http://cvm.com/role/LossPerCommonShare 21 false false R22.htm 000022 - Disclosure - A BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://cvm.com/role/ABasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative A BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details 22 false false R23.htm 000023 - Disclosure - C STOCKHOLDERS EQUITY (Details) Sheet http://cvm.com/role/CStockholdersEquityDetails C STOCKHOLDERS EQUITY (Details) Details 23 false false R24.htm 000024 - Disclosure - C STOCKHOLDERS EQUITY (Details 1) Sheet http://cvm.com/role/CStockholdersEquityDetails1 C STOCKHOLDERS EQUITY (Details 1) Details 24 false false R25.htm 000025 - Disclosure - C STOCKHOLDERS EQUITY (Details 2) Sheet http://cvm.com/role/CStockholdersEquityDetails2 C STOCKHOLDERS EQUITY (Details 2) Details 25 false false R26.htm 000026 - Disclosure - C STOCKHOLDERS EQUITY (Details 3) Sheet http://cvm.com/role/CStockholdersEquityDetails3 C STOCKHOLDERS EQUITY (Details 3) Details 26 false false R27.htm 000027 - Disclosure - C STOCKHOLDERS EQUITY (Details 4) Sheet http://cvm.com/role/CStockholdersEquityDetails4 C STOCKHOLDERS EQUITY (Details 4) Details 27 false false R28.htm 000028 - Disclosure - C STOCKHOLDERS EQUITY (Details 5) Sheet http://cvm.com/role/CStockholdersEquityDetails5 C STOCKHOLDERS EQUITY (Details 5) Details 28 false false R29.htm 000029 - Disclosure - C STOCKHOLDERS EQUITY (Details Narrative) Sheet http://cvm.com/role/CStockholdersEquityDetailsNarrative C STOCKHOLDERS EQUITY (Details Narrative) Details 29 false false R30.htm 000030 - Disclosure - D FAIR VALUE MEASUREMENTS (Details) Sheet http://cvm.com/role/DFairValueMeasurementsDetails D FAIR VALUE MEASUREMENTS (Details) Details 30 false false R31.htm 000031 - Disclosure - D FAIR VALUE MEASUREMENTS (Details 1) Sheet http://cvm.com/role/DFairValueMeasurementsDetails1 D FAIR VALUE MEASUREMENTS (Details 1) Details 31 false false R32.htm 000032 - Disclosure - ERELATED PARTY TRANSACTIONS (Details Narrative ) Sheet http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative ERELATED PARTY TRANSACTIONS (Details Narrative ) Details 32 false false R33.htm 000033 - Disclosure - F COMMITMENTS AND CONTINGENCIES (Details) Sheet http://cvm.com/role/FCommitmentsAndContingenciesDetails F COMMITMENTS AND CONTINGENCIES (Details) Details 33 false false R34.htm 000034 - Disclosure - F COMMITMENTS AND CONTINGENCIES (Details 1) Sheet http://cvm.com/role/FCommitmentsAndContingenciesDetails1 F COMMITMENTS AND CONTINGENCIES (Details 1) Details 34 false false R35.htm 000035 - Disclosure - F COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative F COMMITMENTS AND CONTINGENCIES (Details Narrative) Details 35 false false R36.htm 000036 - Disclosure - G PATENTS (Details) Sheet http://cvm.com/role/GPatentsDetails G PATENTS (Details) Details 36 false false R37.htm 000037 - Disclosure - G PATENTS (Details Narrative) Sheet http://cvm.com/role/GPatentsDetailsNarrative G PATENTS (Details Narrative) Details 37 false false R38.htm 000038 - Disclosure - H LOSS PER COMMON SHARE (Details) Sheet http://cvm.com/role/HLossPerCommonShareDetails H LOSS PER COMMON SHARE (Details) Details 38 false false R39.htm 000039 - Disclosure - H LOSS PER COMMON SHARE (Details 1) Sheet http://cvm.com/role/HLossPerCommonShareDetails1 H LOSS PER COMMON SHARE (Details 1) Details 39 false false R40.htm 000040 - Disclosure - J SUBSEQUENT EVENTS (Details Narrative) Sheet http://cvm.com/role/JSubsequentEventsDetailsNarrative J SUBSEQUENT EVENTS (Details Narrative) Details 40 false false All Reports Book All Reports cvm_10q.htm cvm-20201231.xsd cvm-20201231_cal.xml cvm-20201231_def.xml cvm-20201231_lab.xml cvm-20201231_pre.xml cvm_ex31.htm cvm_ex32.htm http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cvm_10q.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 113, "dts": { "calculationLink": { "local": [ "cvm-20201231_cal.xml" ] }, "definitionLink": { "local": [ "cvm-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "cvm_10q.htm" ] }, "labelLink": { "local": [ "cvm-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cvm-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cvm-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 384, "entityCount": 1, "hidden": { "http://cvm.com/20201231": 3, "http://fasb.org/us-gaap/2019-01-31": 11, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 20 }, "keyCustom": 78, "keyStandard": 272, "memberCustom": 32, "memberStandard": 13, "nsprefix": "cvm", "nsuri": "http://cvm.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://cvm.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://cvm.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://cvm.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://cvm.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - PATENTS", "role": "http://cvm.com/role/PATENTS", "shortName": "PATENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - LOSS PER COMMON SHARE", "role": "http://cvm.com/role/LossPerCommonShare", "shortName": "LOSS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - SUBSEQUENT EVENTS", "role": "http://cvm.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)", "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)", "role": "http://cvm.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://cvm.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://cvm.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED BALANCE SHEETS", "role": "http://cvm.com/role/CondensedBalanceSheets", "shortName": "CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - PATENTS (Tables)", "role": "http://cvm.com/role/PatentsTables", "shortName": "PATENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - LOSS PER COMMON SHARE (Tables)", "role": "http://cvm.com/role/LossPerCommonShareTables", "shortName": "LOSS PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31_us-gaap_PatentsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - A BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://cvm.com/role/ABasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "A BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31_us-gaap_PatentsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31_cvm_IncentiveStockOptionPlansMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - C STOCKHOLDERS EQUITY (Details)", "role": "http://cvm.com/role/CStockholdersEquityDetails", "shortName": "C STOCKHOLDERS EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31_cvm_IncentiveStockOptionPlansMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - C STOCKHOLDERS EQUITY (Details 1)", "role": "http://cvm.com/role/CStockholdersEquityDetails1", "shortName": "C STOCKHOLDERS EQUITY (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - C STOCKHOLDERS EQUITY (Details 2)", "role": "http://cvm.com/role/CStockholdersEquityDetails2", "shortName": "C STOCKHOLDERS EQUITY (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31_cvm_SeriesNMember", "decimals": "0", "first": true, "lang": null, "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - C STOCKHOLDERS EQUITY (Details 3)", "role": "http://cvm.com/role/CStockholdersEquityDetails3", "shortName": "C STOCKHOLDERS EQUITY (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31_cvm_SeriesNMember", "decimals": "0", "first": true, "lang": null, "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfDerivativeLiabilitiesAtFairValue", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:FairValueOfSeriesWWarrants", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - C STOCKHOLDERS EQUITY (Details 4)", "role": "http://cvm.com/role/CStockholdersEquityDetails4", "shortName": "C STOCKHOLDERS EQUITY (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfDerivativeLiabilitiesAtFairValue", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:FairValueOfSeriesWWarrants", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ExercisedWarrantsRecordedAsEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2019-10-01to2019-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:EquityWarrantsExercised", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - C STOCKHOLDERS EQUITY (Details 5)", "role": "http://cvm.com/role/CStockholdersEquityDetails5", "shortName": "C STOCKHOLDERS EQUITY (Details 5)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ExercisedWarrantsRecordedAsEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2019-10-01to2019-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:EquityWarrantsExercised", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:PrepaidExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - C STOCKHOLDERS EQUITY (Details Narrative)", "role": "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "shortName": "C STOCKHOLDERS EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:PrepaidExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - D FAIR VALUE MEASUREMENTS (Details)", "role": "http://cvm.com/role/DFairValueMeasurementsDetails", "shortName": "D FAIR VALUE MEASUREMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - D FAIR VALUE MEASUREMENTS (Details 1)", "role": "http://cvm.com/role/DFairValueMeasurementsDetails1", "shortName": "D FAIR VALUE MEASUREMENTS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherInterestAndDividendIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - ERELATED PARTY TRANSACTIONS (Details Narrative )", "role": "http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative", "shortName": "ERELATED PARTY TRANSACTIONS (Details Narrative )", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherInterestAndDividendIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:FinanceLeaseLiabilityPaymentsDueRemainderOfYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - F COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://cvm.com/role/FCommitmentsAndContingenciesDetails", "shortName": "F COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:FinanceLeaseLiabilityPaymentsDueRemainderOfYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - F COMMITMENTS AND CONTINGENCIES (Details 1)", "role": "http://cvm.com/role/FCommitmentsAndContingenciesDetails1", "shortName": "F COMMITMENTS AND CONTINGENCIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - F COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative", "shortName": "F COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - G PATENTS (Details)", "role": "http://cvm.com/role/GPatentsDetails", "shortName": "G PATENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - G PATENTS (Details Narrative)", "role": "http://cvm.com/role/GPatentsDetailsNarrative", "shortName": "G PATENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - H LOSS PER COMMON SHARE (Details)", "role": "http://cvm.com/role/HLossPerCommonShareDetails", "shortName": "H LOSS PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "lang": null, "name": "cvm:NetLossAvailableToCommonShareholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - H LOSS PER COMMON SHARE (Details 1)", "role": "http://cvm.com/role/HLossPerCommonShareDetails1", "shortName": "H LOSS PER COMMON SHARE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)", "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromWarrantExercises", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - J SUBSEQUENT EVENTS (Details Narrative)", "role": "http://cvm.com/role/JSubsequentEventsDetailsNarrative", "shortName": "J SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2021-01-01to2021-02-05_us-gaap_SubsequentEventMember", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromWarrantExercises", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)", "role": "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - OPERATIONS AND FINANCING", "role": "http://cvm.com/role/OperationsAndFinancing", "shortName": "OPERATIONS AND FINANCING", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - STOCKHOLDERS EQUITY", "role": "http://cvm.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2020-10-01to2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 45, "tag": { "cvm_AdditionalSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional shares of common stock" } } }, "localname": "AdditionalSharesOfCommonStock", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_AdoptionOfNewAccountingStandard": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Adoption of new accounting standard" } } }, "localname": "AdoptionOfNewAccountingStandard", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_CapitalizablePatentCostsIncludedInCurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Capitalizable patent costs included in current liabilities" } } }, "localname": "CapitalizablePatentCostsIncludedInCurrentLiabilities", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_CashPaidRelatedToFinanceLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash paid related to finance leases" } } }, "localname": "CashPaidRelatedToFinanceLeases", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CashPaidRelatedToFinanceLeasesInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash paid related to finance leases interest" } } }, "localname": "CashPaidRelatedToFinanceLeasesInterest", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ClinicalServiceTrial": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Clinical service trial" } } }, "localname": "ClinicalServiceTrial", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CommonStockContributedToEmployeeBenefitPlan": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock contributed to 401(k) plan" } } }, "localname": "CommonStockContributedToEmployeeBenefitPlan", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants [Member]", "verboseLabel": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_ConsultantsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants One [Member]" } } }, "localname": "ConsultantsOneMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_ConsultingAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreements [Member]" } } }, "localname": "ConsultingAgreementsMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_CostIncurredInitial": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exploration costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.", "label": "Cost incurred, initial" } } }, "localname": "CostIncurredInitial", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CostToImproveTheMaufacturingFacility": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cost to improve the maufacturing facility" } } }, "localname": "CostToImproveTheMaufacturingFacility", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_EquityBasedCompensationEmployeesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Equity based compensation - employees, amount" } } }, "localname": "EquityBasedCompensationEmployeesAmount", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_EquityBasedCompensationEmployeesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity based compensation - employees, shares" } } }, "localname": "EquityBasedCompensationEmployeesShares", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "cvm_EquityWarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Exercise price]", "verboseLabel": "Exercise price" } } }, "localname": "EquityWarrantsExercisePrice", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails5" ], "xbrltype": "perShareItemType" }, "cvm_EquityWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } }, "localname": "EquityWarrantsExercised", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails5" ], "xbrltype": "sharesItemType" }, "cvm_ErgomedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ergomed [Member]", "verboseLabel": "Ergomed [Member]" } } }, "localname": "ErgomedMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_EstimatedCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Estimated cost" } } }, "localname": "EstimatedCost", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ExerciseOfDerivativeLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Exercise of derivative liabilities" } } }, "localname": "ExerciseOfDerivativeLiabilities", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price" } } }, "localname": "ExercisePrice", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "perShareItemType" }, "cvm_ExercisedWarrantsRecordedAsEquityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants recorded as equity exercised" } } }, "localname": "ExercisedWarrantsRecordedAsEquityTableTextBlock", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cvm_ExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiration date", "verboseLabel": "Expiration date" } } }, "localname": "ExpirationDate", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "cvm_ExpirationDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiration date description" } } }, "localname": "ExpirationDateDescription", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "cvm_FacilityImprovementCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Facility improvement costs" } } }, "localname": "FacilityImprovementCosts", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Realized and unrealized (gains) and losses" } } }, "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesAaWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series AA warrants" } } }, "localname": "FairValueOfSeriesAaWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesBbWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series BB warrants" } } }, "localname": "FairValueOfSeriesBbWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesCcWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series CC warrants" } } }, "localname": "FairValueOfSeriesCcWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesHhWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series HH warrants" } } }, "localname": "FairValueOfSeriesHhWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesWWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series W warrants" } } }, "localname": "FairValueOfSeriesWWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesZwarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series Z warrants" } } }, "localname": "FairValueOfSeriesZwarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesZzWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series ZZ warrants" } } }, "localname": "FairValueOfSeriesZzWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Nine months ending September 30, 2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueRemainderOfYear", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_FinanceLeaseObligationIncludedInAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Finance lease obligation included in accounts payable" } } }, "localname": "FinanceLeaseObligationIncludedInAccountsPayable", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_FinanceLeaseObligationsNetOfCurrentPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid", "label": "[Finance lease obligations, net of current portion]", "verboseLabel": "Finance lease obligations, net of current portion" } } }, "localname": "FinanceLeaseObligationsNetOfCurrentPortion", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_FinanceLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Finance lease right of use assets]", "verboseLabel": "Finance lease right of use assets" } } }, "localname": "FinanceLeaseRightOfUseAssets", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_FinancingCostsIncludedInCurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Financing costs included in current liabilities" } } }, "localname": "FinancingCostsIncludedInCurrentLiabilities", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesAaWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series AA warrants" } } }, "localname": "GainLossSeriesAaWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesBbWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series BB warrants" } } }, "localname": "GainLossSeriesBbWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesCcWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series CC warrants" } } }, "localname": "GainLossSeriesCcWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesFfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series FF warrants" } } }, "localname": "GainLossSeriesFfWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesHhWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series HH warrants" } } }, "localname": "GainLossSeriesHhWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesJjWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series JJ warrants" } } }, "localname": "GainLossSeriesJjWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesLlWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series LL warrants" } } }, "localname": "GainLossSeriesLlWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesVWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series V warrants" } } }, "localname": "GainLossSeriesVWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesWWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series W warrants" } } }, "localname": "GainLossSeriesWWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesZWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series Z warrants" } } }, "localname": "GainLossSeriesZWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossSeriesZzWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gains (losses) on Series ZZ warrants" } } }, "localname": "GainLossSeriesZzWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_IncentiveStockBonusPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Stock Bonus Plan [Member]" } } }, "localname": "IncentiveStockBonusPlansMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cvm_IncentiveStockOptionPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Stock Option Plans [Member]" } } }, "localname": "IncentiveStockOptionPlansMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cvm_IncreasedLeasePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increased lease payments" } } }, "localname": "IncreasedLeasePayments", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_IssueDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issue date" } } }, "localname": "IssueDate1", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "stringItemType" }, "cvm_LandlordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Landlord [Member]" } } }, "localname": "LandlordMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_LeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Agreement [Member]" } } }, "localname": "LeaseAgreementMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_LeaseLiabilitiesCurrentPortion": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Lease liabilities, current portion" } } }, "localname": "LeaseLiabilitiesCurrentPortion", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvm_LesseeOperatingLeaseLiabilityPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total future minimum lease obligation]", "verboseLabel": "Total future minimum lease obligation" } } }, "localname": "LesseeOperatingLeaseLiabilityPayments", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Nine months ending September 30, 2021]", "verboseLabel": "Nine months ending September 30, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "cvm_MaturityYears": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maturity years" } } }, "localname": "MaturityYears", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "cvm_ModificationOfWarrant": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Modification of warrants 1]", "verboseLabel": "Modification of warrants" } } }, "localname": "ModificationOfWarrant", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ModificationOfWarrants": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Modification of warrants" } } }, "localname": "ModificationOfWarrants", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ModificationOfWarrantsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Modification of warrants]", "verboseLabel": "Modification of warrants" } } }, "localname": "ModificationOfWarrantsAmount", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_NetBookValueOperatingLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and re", "label": "Net book value operating lease right of use assets" } } }, "localname": "NetBookValueOperatingLeaseRightOfUseAssets", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_NetLossAvailableToCommonShareholdersBasic": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Net loss available to common shareholders - basic]", "verboseLabel": "Net loss available to common shareholders - basic" } } }, "localname": "NetLossAvailableToCommonShareholdersBasic", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "cvm_NetOfDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net of discount" } } }, "localname": "NetOfDiscount", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_NetPresentValueOfLeaseFinanceLeaseObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Net present value of lease finance lease obligations" } } }, "localname": "NetPresentValueOfLeaseFinanceLeaseObligations", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_NonEmployeesStockBasedCompensationExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Non- Employees stock based compensation expense" } } }, "localname": "NonEmployeesStockBasedCompensationExpense", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails2" ], "xbrltype": "monetaryItemType" }, "cvm_NonQualifiedOptionsPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Non-Qualified Stock Option Plans [Member]]", "verboseLabel": "Non-Qualified Stock Option Plans [Member]" } } }, "localname": "NonQualifiedOptionsPlanMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_NonQualifiedStockOptionsPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Qualified Stock Option Plans [Member]" } } }, "localname": "NonQualifiedStockOptionsPlansMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cvm_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Options issued]", "verboseLabel": "Options issued" } } }, "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid consulting services paid with issuance of common stock" } } }, "localname": "PrepaidConsultingServicesPaidWithIssuanceOfCommonStock", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_PrepaidExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Prepaid expenses]", "verboseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenses", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromEquityWarrantExercises": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds" } } }, "localname": "ProceedsFromEquityWarrantExercises", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails5" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromTheSaleOfCommonStockAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from the sale of common stock, amount" } } }, "localname": "ProceedsFromTheSaleOfCommonStockAmount", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromTheSaleOfCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from the sale of common stock, shares" } } }, "localname": "ProceedsFromTheSaleOfCommonStockShares", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "cvm_PropertyPlantEquipmentIncludedInCurrentLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Property and equipment included in current liabilities" } } }, "localname": "PropertyPlantEquipmentIncludedInCurrentLiabilities", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_SPAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SPA [Member]" } } }, "localname": "SPAMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_ScheduleOfDerivativeLiabilitiesAtFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tabular disclosure of derivative liabilities at fair value" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValue", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative liabilities, warrants and other options" } } }, "localname": "ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of gains and (losses) on derivative liabilities" } } }, "localname": "ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock options, stock bonuses and compensation granted by the Company" } } }, "localname": "ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cvm_SeriesAaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series AA [Member]" } } }, "localname": "SeriesAaMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesBBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series BB [Member]" } } }, "localname": "SeriesBBMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesCcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series CC [Member]" } } }, "localname": "SeriesCcMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesFFMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series FF [Member]" } } }, "localname": "SeriesFFMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesHhMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series HH [Member]" } } }, "localname": "SeriesHhMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesMmMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series MM [Member]" } } }, "localname": "SeriesMmMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N [Member]" } } }, "localname": "SeriesNMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesNNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series NN [Member]" } } }, "localname": "SeriesNNMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesNWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N Warrants [Member]" } } }, "localname": "SeriesNWarrantsMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesOOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series OO [Member]" } } }, "localname": "SeriesOOMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails5" ], "xbrltype": "domainItemType" }, "cvm_SeriesRRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series RR [Member]" } } }, "localname": "SeriesRRMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesSSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series SS [Member]" } } }, "localname": "SeriesSSMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetails5" ], "xbrltype": "domainItemType" }, "cvm_SeriesTTMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series TT [Member]" } } }, "localname": "SeriesTTMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetails5", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesUUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series UU [Member]" } } }, "localname": "SeriesUUMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesUUWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series UU warrants [Member]" } } }, "localname": "SeriesUUWarrantsMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesWWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series W Warrants [Member]" } } }, "localname": "SeriesWWarrantsMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series X [Member]" } } }, "localname": "SeriesXMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesYMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Y [Member]" } } }, "localname": "SeriesYMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Z [Member]" } } }, "localname": "SeriesZMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesZZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series ZZ [Member]" } } }, "localname": "SeriesZZMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_ShareIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Share issuance costs" } } }, "localname": "ShareIssuanceCosts", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_SharesIssuableUponExerciseOfWarrantOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issuable upon exercise of warrant/options" } } }, "localname": "SharesIssuableUponExerciseOfWarrantOptions", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "sharesItemType" }, "cvm_StockBonusPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Bonus Plans [Member]" } } }, "localname": "StockBonusPlansMember", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cvm_SuppliesUsedForRDAndManufacturing": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Supplies used for R&D and manufacturing]", "verboseLabel": "Supplies used for R&D and manufacturing" } } }, "localname": "SuppliesUsedForRDAndManufacturing", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_TotalFairValueOfDerivativeLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total warrant liabilities" } } }, "localname": "TotalFairValueOfDerivativeLiabilities", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_WarrantExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant exercise price" } } }, "localname": "WarrantExercisePrice", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "cvm_WarrantExercisesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrant exercises, amount" } } }, "localname": "WarrantExercisesAmount", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_WarrantExercisesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant exercises, shares" } } }, "localname": "WarrantExercisesShares", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "cvm_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Warrants exercised]", "verboseLabel": "Warrants exercised" } } }, "localname": "WarrantsExercised", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_WeightedAverageSharesOutstandingBasic": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Weighted average shares outstanding - basic]", "verboseLabel": "Weighted average shares outstanding - basic" } } }, "localname": "WeightedAverageSharesOutstandingBasic", "nsuri": "http://cvm.com/20201231", "presentation": [ "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r20", "r89", "r90", "r116" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r60", "r95", "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of patent costs" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/GPatentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/HLossPerCommonShareDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/HLossPerCommonShareDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/HLossPerCommonShareDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r88", "r199", "r213" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r37" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r12", "r13", "r14" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Non current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r128", "r140" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date Axis" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r128", "r140" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type Axis" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r26", "r62" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets", "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "[Cash and Cash Equivalents, Period Increase (Decrease)]", "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r71", "r114", "r127" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right Axis" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetails5", "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetails5", "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Common stock price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r33", "r109", "r203", "r217" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r108", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "F. COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesHeldInEmployeeTrustShares": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Number of common stock held in a trust that has been set up specifically to accumulate stock for the sole purpose of distribution to participating employees but not yet earned.", "label": "Common stock shares held" } } }, "localname": "CommonStockSharesHeldInEmployeeTrustShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r111" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.01 par value - 600,000,000 shares authorized; 39,767,058 and 38,730,150 shares issued and outstanding at December 31, 2020 and September 30, 2020, respectively", "verboseLabel": "Common stock valued" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Total expense" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r16", "r17", "r112", "r200", "r201", "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "[Debt Instrument, Description]", "verboseLabel": "Expiration date description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r120", "r123", "r125", "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Incremental cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositAssets": { "auth_ref": [ "r36" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.", "label": "Deposits" } } }, "localname": "DepositAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r60", "r105" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r38", "r40", "r155", "r184" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative instruments" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r154" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Gain on derivative instruments" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainOnDerivative": { "auth_ref": [ "r154" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.", "label": "Gain on derivatives (1)" } } }, "localname": "DerivativeGainOnDerivative", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative instruments, current portion" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative instruments, net of current portion" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesReportingOfDerivativeActivity": { "auth_ref": [ "r67", "r72", "r152" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.", "label": "Derivative Instruments" } } }, "localname": "DerivativesReportingOfDerivativeActivity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases": { "auth_ref": [ "r107", "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Lease description" } } }, "localname": "DescriptionOfLesseeLeasingArrangementsCapitalLeases", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DueToOfficersOrStockholdersCurrent": { "auth_ref": [ "r15", "r69", "r174", "r212", "r222" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to employees" } } }, "localname": "DueToOfficersOrStockholdersCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r46", "r74", "r78", "r79", "r80", "r81", "r85", "r206", "r219" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "BASIC", "verboseLabel": "Basic loss per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss per share - basic" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common share" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r46", "r74", "r78", "r79", "r80", "r81", "r85", "r206", "r219" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "DILUTED", "verboseLabel": "Diluted loss earnings per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss per share - diluted" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r67", "r82", "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "H. LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/LossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employees stock based compensation expense" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r121", "r122", "r126", "r157", "r180" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level Axis" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "D. FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r121", "r122", "r126", "r157", "r181" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r121", "r122", "r126", "r157", "r182" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r121", "r122", "r126", "r157", "r183" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r156", "r157" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Measured at fair value on a recurring basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r158", "r161" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": { "auth_ref": [ "r159" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales]", "negatedLabel": "Exercises" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/DFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r166", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance lease liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Schedule of future minimum payments under finance leases" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r166" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance lease obligations, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Total future minimum lease obligation" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.", "label": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Less imputed interest on finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r167", "r170" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "[Finance Lease, Principal Payments]", "negatedLabel": "Payments on obligations under finance lease" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r165" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance lease right of use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r171", "r173" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Weighted average discount rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Patent useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/ABasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months]", "verboseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/GPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year]", "verboseLabel": "Nine months ending September 30, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/GPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]", "verboseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/GPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Finite-Lived Intangible Assets, Amortization Expense, Year Five]", "verboseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/GPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Finite-Lived Intangible Assets, Amortization Expense, Year Four]", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/GPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Finite-Lived Intangible Assets, Amortization Expense, Year Three]", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/GPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Finite-Lived Intangible Assets, Amortization Expense, Year Two]", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/GPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r96", "r97", "r100", "r103", "r185" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class Axis" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/ABasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r96", "r99" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/ABasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "[Finite-Lived Intangible Assets, Net]", "verboseLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/GPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r100" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Patent costs, net" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r153" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Net loss on warrant liabilities" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r60", "r208" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "[Gain (Loss) on Sale of Derivatives]", "verboseLabel": "Gain on derivative instruments" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r67", "r94", "r98" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Patents" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r44", "r74", "r198", "r204", "r220" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r43", "r67", "r144", "r145", "r146", "r147", "r148", "r149", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "[Increase (Decrease) in Accrued Liabilities]", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.", "label": "[Increase (Decrease) in Due to Officers and Stockholders]", "verboseLabel": "Due to employees" } } }, "localname": "IncreaseDecreaseInDueToOfficersAndStockholders", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "(Increase)/decrease in assets:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase/(decrease) in liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "[Increase (Decrease) in Other Operating Liabilities]", "verboseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "verboseLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Receivables]", "verboseLabel": "Receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental shares underlying dilutive \"in the money\" warrants" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "G. PATENTS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/PATENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PATENTS" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest expense" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r207" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r55", "r57", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r35", "r92" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Supplies used for R&D and manufacturing" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r60" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Share-based payments for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating lease expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Net present value of operating lease obligation" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "[Lessee, Operating Lease, Liability, Payments, Due after Year Five]", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "[Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months]", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "[Lessee, Operating Lease, Liability, Payments, Due Year Five]", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "[Lessee, Operating Lease, Liability, Payments, Due Year Four]", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "[Lessee, Operating Lease, Liability, Payments, Due Year Three]", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "[Lessee, Operating Lease, Liability, Payments, Due Year Two]", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]", "negatedLabel": "Less imputed interest on operating lease obligation" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 28.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r202", "r215" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r86", "r87" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "B. OPERATIONS AND FINANCING" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/OperationsAndFinancing" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r56" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 24.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r56" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 25.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r56", "r58", "r61" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 26.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r41", "r42", "r45", "r61", "r83", "r205", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToParentDiluted": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Net loss available to common shareholders - diluted" } } }, "localname": "NetIncomeLossAttributableToParentDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r74", "r76" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "[Net Income (Loss) Available to Common Stockholders, Basic]", "totalLabel": "Net loss available to common shareholders", "verboseLabel": "Net loss available to common shareholders - basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": { "auth_ref": [ "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Options issued" } } }, "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r166" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease - liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r166" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r166" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease obligations, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r168", "r170" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid related to operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r165" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options and Warrants" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/HLossPerCommonShareDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r221" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Grant income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInterestAndDividendIncome": { "auth_ref": [ "r209" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other.", "label": "Deemed dividend" } } }, "localname": "OtherInterestAndDividendIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingGainsLosses": { "auth_ref": [ "r50" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.", "label": "Other non-operating gains" } } }, "localname": "OtherNonoperatingGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r49" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other research and development expense.", "label": "Research and development expenses" } } }, "localname": "OtherResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/ABasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r54" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "[Payments of Stock Issuance Costs]", "negatedLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r52" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "[Payments to Acquire Intangible Assets]", "negatedLabel": "Expenditures for patent costs" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r52" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r128", "r140" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r5", "r93" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r53" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r53" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from the purchase of stock by officer" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r51" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from the sale of equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r53" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercises of warrants and options", "terseLabel": "Proceeds from exercise of options and warrants", "verboseLabel": "Proceeds from warrants exercised" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://cvm.com/role/JSubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r106", "r216" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r27", "r67", "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATIONS AND FINANCING" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r124", "r175", "r176", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "E. RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r143", "r224" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r67", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Unvested Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/HLossPerCommonShareDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r113", "r214" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Proceeds from the sale of common stock" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Public offering price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of antidilutive securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/LossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock": { "auth_ref": [ "r117", "r118", "r119", "r128", "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an equity-based arrangement (such as stock or unit options and stock or unit awards) with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.", "label": "Stock-based compensation expense" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of basic and diluted loss per-share computations" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/LossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of total estimated future amortization" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/PatentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r132", "r137", "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r59" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Equity based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Total shares reserved under plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Remaining options/shares under plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Options expired", "verboseLabel": "Warrants expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails1", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Options forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options granted", "verboseLabel": "Stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails1", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r127", "r130" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails", "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "[Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price]", "verboseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Shares reserved for outstanding options" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Fair value of stock option" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r115", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Stock-Based Compensation" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "verboseLabel": "Shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeasesPolicyTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy election for short-term lease to recognize lease payments on straight-line basis over lease term and variable lease payments as incurred.", "label": "Leases" } } }, "localname": "ShortTermLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r34", "r111" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/ABasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://cvm.com/role/CStockholdersEquityDetails", "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetails5", "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/DFairValueMeasurementsDetails", "http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/HLossPerCommonShareDetails1", "http://cvm.com/role/JSubsequentEventsDetailsNarrative", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/ABasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://cvm.com/role/CStockholdersEquityDetails", "http://cvm.com/role/CStockholdersEquityDetails3", "http://cvm.com/role/CStockholdersEquityDetails5", "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/DFairValueMeasurementsDetails", "http://cvm.com/role/ErelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/HLossPerCommonShareDetails1", "http://cvm.com/role/JSubsequentEventsDetailsNarrative", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Stock Compensation Plan [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "401(k) contributions paid in common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock issued to nonemployees for service, shares", "verboseLabel": "Common stock issued for service, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetailsNarrative", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Purchase of stock by officer, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r111", "r113", "r134" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Option exercises, shares", "verboseLabel": "Options exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CStockholdersEquityDetails1", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "401(k) contributions paid in common stock, amount" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock issued to nonemployees for service, amount" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r111", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock, amount" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Purchase of stock by officer, amount" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r34", "r111", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Option exercises, amount" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r23", "r24", "r91" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "C. STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r169", "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease rental income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/FCommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/JSubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/JSubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/JSubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "J. SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r77", "r81" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "[Weighted Average Number of Shares Outstanding, Diluted]", "terseLabel": "Weighted average shares outstanding - diluted", "verboseLabel": "DILUTED" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r75", "r81" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "[Weighted Average Number of Shares Outstanding, Basic]", "terseLabel": "Weighted average shares outstanding - basic", "verboseLabel": "BASIC" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/HLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77904769&loc=SL2265659-115463" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20517-108367" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16701-113920" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117415099&loc=d3e34841-113949" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=108795181&loc=d3e32400-112679" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164451&loc=d3e36991-112694" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888369&loc=SL77918418-209957" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(17))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r225": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r226": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r227": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r228": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r229": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7,9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(7))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" } }, "version": "2.1" } ZIP 57 0001654954-21-001609-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-21-001609-xbrl.zip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end